entecavir profile

entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	135398508
CHEMBL ID	713
CHEBI ID	59902
CHEBI ID	473990
SCHEMBL ID	28648
SCHEMBL ID	15198001
MeSH ID	M0370336
PubMed CID	57339144
CHEMBL ID	2426364
CHEBI ID	95086
SCHEMBL ID	19730381
MeSH ID	M0370336

Synonym
AC-1593
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-1h-purin-6-one
bms-200475
baraclude
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-1h-purin-6-one
142217-69-4
entecavir
6-h-purin-6-one-,2-amino-1,9-dihydro-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]
sq-34676
209216-23-9
entecavir (anhydrous)
entecavir anhydrous
DB00442
anhydrous entecavir
NCGC00164563-01
hsdb 7334
6h-purin-6-one, 2-amino-1,9-dihydro-9-((1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-
sq 34676
entecavir [usan:inn]
bms 200475
CHEMBL713
sq34676
bms-200475-01
CHEBI:59902 ,
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-3h-purin-6-one
D07896
entecavir (inn)
QDGZDCVAUDNJFG-FXQIFTODSA-N
chebi:473990 ,
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1,9-dihydro-6h-purin-6-one
A807868
2-amino-9-[(1r,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylene-cyclopentyl]-3h-purin-6-one hydrate;entecavir
2-amino-1,9-dihydro-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one
nnu2o4609d ,
unii-nnu2o4609d
cas-142217-69-4
dtxcid2026446
dtxsid4046446 ,
tox21_112192
bms 200475-01
unii-5968y6h45m
AKOS015920226
2-amino-9-((1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1,9-dihydro-6h-purin-6-one
entecavir [who-dd]
entecavir [hsdb]
entecavir [inn]
entecavir [mi]
AKOS015854916
6h-purin-6-one, 2-amino-1,9-dihydro-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-
AM20080880
(1r,3s,4s)-entecavir
BRD-K08206212-001-01-2
CS-3160
HY-13623
SCHEMBL28648
SCHEMBL15198001
E0899
9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]guanine
mfcd00907887
sq 34,676
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one
AKOS025312554
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-6,9-dihydro-3h-purin-6-one
bms200475
GS-6386
entecavir, >=98% (hplc)
2-amino-9-((1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1h-purin-6(9h)-one
NCGC00164563-09
bdbm50248008
Q418586
1333204-94-6
AR-270/43507901
2-amino-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-1,9-dihydro-6h-purin-6-one
CCG-267218
NCGC00164563-04
NCGC00164563-13
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-hydroxymethyl-2-methylenecyclopentyl]-1,9-dihydro-6h-purin-6-one
2-amino-9-[(1s,3r,4s)-4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl]-1h-purin-6-one
S5246
NCGC00164563-06
EN300-37158607
entecavir (mart.)
entecavirum
j05af10
entecavir (usp monograph)
entecavir monohydrate (ep monograph)
entecavir monohydrate (usp-rs)
[2-(phenylamino)benzene-1,4-diyl]bis{[4-(pyrrolidin-1-yl)piperidin-1-yl]methanone}
NCGC00344623-02
2-phenylamino-1,4-bis(4-(pyrrolidinyl)piperidinyl)benzamide
S7088
(2-(phenylamino)-1,4-phenylene)bis((4-(pyrrolidin-1-yl)piperidin-1-yl)methanone)
BP-21087
gtpl8232
n-phenyl-2,5-bis[4-(pyrrolidin-1-yl)piperidine-1-carbonyl]aniline
bdbm50440614
chembl2426364 ,
unc1215 ,
CS-1646
HY-15649
MLS006011024
smr004702819
1415800-43-9
2-phenylamino-1,4-bis[4-(pyrrolidinyl)-piperidinyl)benzamide]
unc 1215
2-phenylamino-1,4-[4-(pyrrolidinyl)piperidinyl)benzamide
AC-32715
AKOS024458279
unc-1215
[3-anilino-4-(4-pyrrolidin-1-ylpiperidine-1-carbonyl)phenyl]-(4-pyrrolidin-1-ylpiperidin-1-yl)methanone
EX-A193
CHEBI:95086
HMS3652P22
unc1215, >=98% (hplc)
mfcd22683289
NCGC00344623-12
SCHEMBL19730381
n-phenyl-2,5-bis({[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl})aniline
SW220042-1
FT-0713405
BCP07393
Q27089089
AS-16797
methanone, 1,1'-[2-(phenylamino)-1,4-phenylene]bis[1-[4-(1-pyrrolidinyl)-1-piperidinyl]-
SB19337
HMS3426E15
HMS3744C05
CCG-269911
A857599
DTXSID301026044

Excerpt	Reference	Relevance
" Entecavir was well tolerated, with no patients discontinuing study drug due to adverse events."	( Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Imazeki, F; Kage, M; Katano, Y; Kumada, H; Moriyama, M; Omata, M; Sata, M; Seriu, T; Suzuki, F; Toyoda, J, 2008)	0.35
" The frequency of adverse events with entecavir and placebo was comparable."	( Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy. Brandão-Mello, CE; Brett-Smith, H; Cassetti, I; Gazzard, B; Hall, A; Huang, AK; Mendes-Corrêa, MC; Pessôa, MG; Phiri, P; Soriano, V, 2008)	0.35
" There were no significant adverse effects from these drugs and no alteration of renal function during the follow-up period."	( Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB, 2010)	0.36
"Therapy with ETV and/or TDF seems to be efficient and safe when used in the prophylaxis and treatment of HBV recurrence after liver transplantation."	( Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. de la Cruz-Lombardo, J; Jiménez-Pérez, M; Lozano-Rey, JM; Mongil Poce, L; Rodrigo-López, JM; Sáez-Gómez, AB, 2010)	0.36
" There were no serious adverse events."	( Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Fung, J; Lai, CL; Seto, WK; Wong, DK; Yuen, JC; Yuen, MF, 2011)	0.37
" Adverse event rates were comparable between groups."	( Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Beebe, S; Bialkowska, J; Brown, RS; Cheinquer, H; Cooney, E; Jeffers, L; Leung, N; Liaw, YF; Myers, RP; Peng, CY; Raptopoulou-Gigi, M; Sarin, SK; Tang, S; Tanwandee, T; Tsai, N, 2011)	0.37
"To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association."	( Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Akarca, US; Beebe, S; Chang, TT; Manns, MP; Min, A; Pangerl, A; Sievert, W; Tsai, N; Wongcharatrawee, S; Yoon, SK; Yu, M, 2012)	0.38
" No patients discontinued treatment due to adverse events."	( Efficacy and safety of entecavir in clinical practice in treatment-naive Caucasian chronic hepatitis B patients. Bonet, L; Buti, M; Diago, M; García-Samaniego, J; Morillas, RM; Palau, A; Pérez, J; Prieto, M; Rodríguez, M; Solà, R; Testillano, M, 2012)	0.38
" Several studies suggest that NAs long-term administration have been associated with low rates of serious adverse events (AEs), including lactic acidosis, renal function impairment, osteopenia and osteoporosis."	( Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Ridruejo, E; Silva, MO, 2012)	0.38
" Laboratory test results, clinical outcomes, and drug-related adverse events were compared among groups."	( Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013)	0.39
"Tenofovir and entecavir are effective and safe for long-term use in patients with compensated or decompensated cirrhosis from HBV infection."	( Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Akbal, E; Akin, E; Alkan, E; Ataseven, H; Aygün, C; Başar, O; Baykal, O; Coban, S; Demir, M; Gülşen, MT; Ibiş, M; Koçkar, MC; Köklü, S; Köksal, AŞ; Küçükazman, M; Nadir, I; Ozdil, K; Pürnak, T; Tuna, Y; Yildirim, B; Yüksel, I; Yüksel, O, 2013)	0.39
" No severe adverse events associated with entecavir or tenofovir were reported."	( Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. Arenas, J; Canós, AP; Díaz-Sánchez, A; Jiménez, M; Miquel, M; Núñez, Ó; Trapero-Marugán, M, )	0.13
" In addition, no obvious adverse reactions were observed during ETV treatment."	( The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus. Hua, HY; Huang, LH; Li, YG; Niu, XH; Qiu, YW; Wu, HY; Wu, PF; Yang, XJ; Yao, SZ; Zhu, HY, 2013)	0.39
"ETV is safe and effective in patients with advanced schistosomiasis and HBV co-infection."	( The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus. Hua, HY; Huang, LH; Li, YG; Niu, XH; Qiu, YW; Wu, HY; Wu, PF; Yang, XJ; Yao, SZ; Zhu, HY, 2013)	0.39
" Adverse event rates were comparable between treatment-na€ıve and treatment-experienced patients with compensated liver disease, but were higher in decompensated than in compensated patients, consistent with previous reports in these patients with more advanced disease."	( Efficacy and safety of entecavir treatment in a heterogeneous CHB population from a ‘real-world’ clinical practice setting in China. Cheng, M; Cohen, D; Hou, JL; Jia, JD; Llamoso, C; Ren, H; Tan, DM; Tang, H; Tang, X; Wang, YM; Wei, L; Zhao, W, 2013)	0.39
"Entecavir (ETV) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established."	( Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Adrover, R; Cocozzella, D; Estepo, C; Fainboim, H; Fernandez, N; Gadano, AC; Galdame, O; Levi, D; Mandó, OG; Marciano, S; Mendizabal, M; Muñoz, AE; Paz, S; Reggiardo, MV; Ridruejo, E; Romero, GA; Schroder, T; Silva, MO, )	0.13
" No serious adverse events were reported."	( Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Adrover, R; Cocozzella, D; Estepo, C; Fainboim, H; Fernandez, N; Gadano, AC; Galdame, O; Levi, D; Mandó, OG; Marciano, S; Mendizabal, M; Muñoz, AE; Paz, S; Reggiardo, MV; Ridruejo, E; Romero, GA; Schroder, T; Silva, MO, )	0.13
"TDF and ETV are similarly effective and safe in chronic HBV patients after 24 weeks and 48 weeks of anti-viral therapy."	( Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. Gao, Y; Ke, W; Liu, L; Yang, Y; Ye, X; Zhang, C; Zhou, S, 2014)	0.4
" Entecavir as a potent and safe agent leading to continuous viral suppression proved to be safe and well tolerated therapy."	( Four-year study of entecavir efficacy and safety in nucleos(t)ide-naïve HBeAg positive chronic hepatitis B patients. Ayaz, C; Bayan, K; Celen, MK; Dal, T; Devecil, O; Mert, D; Oruc, EK, 2014)	0.4
" Combination therapy with tenofovir plus entecavir in this setting with multidrug resistance is safe and effective."	( Efficacy and safety of tenofovir in a kidney transplant patient with chronic hepatitis B and nucleos(t)ide multidrug resistance: a case report. Shan, C; Wu, P; Yin, GQ, 2014)	0.4
"This retrospective investigation carried out in Guangdong Province indicated that not only are anti-HBV drugs efficacious for blocking vertical transmission of HBV but also are safe for both mothers and infants when taken by fathers or mothers during the reproduction phases of insemination and pregnancy."	( [Retrospective analysis of the efficacy and safety of anti-hepatitis B virus drugs taken during pregnancy in women from the Guangdong Province]. Chen, X; Gao, W; Li, D; Peng, J; Wen, F; Xia, J; Xu, C; Xu, M; Yao, Z, 2014)	0.4
" There were no treatment discontinuations due to adverse events."	( Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. Andrade, R; Arenas, JI; Bonet, L; Buti, M; Calleja, JL; Castellano, G; Delgado, M; Diago, M; Gallego, A; García-Buey, L; García-Samaniego, J; Gila, A; González-Guirado, A; Gutiérrez, ML; Mas, A; Morillas, RM; Palau, A; Pérez, J; Prieto, M; Rodríguez, M; Romero-Gómez, M; Solà, R; Testillano, M, 2015)	0.42
" No adverse effect was identified in the examined studies."	( The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. An, Y; Chen, S; Du, Y; Gao, S; Liu, L; Zhang, M; Zhang, X, )	0.13
" There was no case with serious adverse event."	( Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients. An, SH; Choe, WH; Chung, HA; Jeong, GW; Jeong, TG; Kim, J; Kim, JH; Kwon, SW; Kwon, SY; Min, JK; Yu, HM; Yun, SU, )	0.13
" ETV, IFN, and the combination of the two are safe in CHB treatment."	( The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis. Fu, LL; Wu, LH; Xiang, Y; Xie, QL; Zhu, Y, 2015)	0.42
" No adverse effects were observed or dose reductions required associated with ETV or TDF."	( Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Abradelo, M; Calvo, J; Cambra, F; Castellano, G; Fernández, I; García, A; Hernández, O; Jiménez, C; Loinaz, C; Manrique, A; Manzano, M, 2015)	0.42
"Maintenance therapy with newer NAs, after discontinuation of HBIG prophylaxis, was safe and effective, with a low rate of serological recurrence and no evident clinical, biochemical, or virological consequences."	( Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Abradelo, M; Calvo, J; Cambra, F; Castellano, G; Fernández, I; García, A; Hernández, O; Jiménez, C; Loinaz, C; Manrique, A; Manzano, M, 2015)	0.42
"Entecavir (ETV) has been shown to be safe and efficacious in randomised controlled trials in highly selected patients with hepatitis B virus (HBV) infection."	( Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Ahn, J; Chu, D; Do, S; Lee, HM; Lim, JK; Lok, AS; Mannalithara, A; Min, A; Nguyen, MH; Pan, CQ; Ray Kim, W; Reddy, KR; Te, H; Tran, T; Trinh, H, 2016)	0.43
" Rates of ALT normalisation, undetectable HBV DNA, HBeAg and HBsAg loss/seroconversion, adverse events (AE) and clinical outcomes were evaluated."	( Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Ahn, J; Chu, D; Do, S; Lee, HM; Lim, JK; Lok, AS; Mannalithara, A; Min, A; Nguyen, MH; Pan, CQ; Ray Kim, W; Reddy, KR; Te, H; Tran, T; Trinh, H, 2016)	0.43
"Entecavir treatment was safe in a large cohort of US patients, but ALT normalisation and hepatitis B virus DNA suppression rates were lower than previously reported in clinical trials."	( Entecavir safety and effectiveness in a national cohort of treatment-naïve chronic hepatitis B patients in the US - the ENUMERATE study. Ahn, J; Chu, D; Do, S; Lee, HM; Lim, JK; Lok, AS; Mannalithara, A; Min, A; Nguyen, MH; Pan, CQ; Ray Kim, W; Reddy, KR; Te, H; Tran, T; Trinh, H, 2016)	0.43
" The adverse responses were recorded."	( Safety and efficacy of mizoribine treatment in nephrotic syndrome complicated with hepatitis B virus infection: a clinical study. Ji, Y; Li, W; Liu, J; Sun, J; Wang, J; Yong, Q; Zhang, H; Zhang, K; Zhang, W, 2016)	0.43
"This study indicates that newer antivirals are effective and safe in HTR with CHB."	( Efficacy and safety of tenofovir, entecavir, and telbivudine for chronic hepatitis B in heart transplant recipients. Andini, R; Durante-Mangoni, E; Falco, E; Iossa, D; Maiello, C; Parrella, A; Ragone, E; Utili, R; Vitrone, M; Zampino, R, 2016)	0.43
" Monitoring viral and liver markers combined with hepatologist consultations may ensure safe follow-up in LDKT recipients with prior resolved HBV infection."	( Safety of Monitoring Viral and Liver Function Markers in Patients With Prior Resolved Hepatitis B Infection After Kidney Transplantation. Chikaraishi, T; Imai, N; Kawarazaki, H; Koitabashi, K; Maekawa, H; Nakazawa, R; Sasaki, H; Shibagaki, Y; Yazawa, M, )	0.13
" The incidence of serious adverse events was low and unrelated to the study medications."	( Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. Byun, KS; Heo, J; Kim, BH; Kim, D; Kim, DJ; Kim, TH; Kweon, YO; Lee, HJ; Lee, KS; Lee, MS; Lee, YS; Lim, YS; Paik, SW; Suh, DJ; Um, SH; Yu, K, 2017)	0.46
"Entecavir (ETV) is effective and safe antiviral agent against hepatitis B virus (HBV) in clinical and real-world setting but, most studies were performed in single institute or have limitation in patient's number."	( Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Kim, CS; Kim, CW; Kim, HY; Lee, CD; Lee, HJ; Llamoso, C; Yu, K, 2018)	0.48
" For the safety assessment, investigators recorded the occurrence of observed and patient-reported adverse events (AEs), as well as laboratory abnormalities."	( Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Kim, CS; Kim, CW; Kim, HY; Lee, CD; Lee, HJ; Llamoso, C; Yu, K, 2018)	0.48
"57%), and 67 adverse drug reactions in 54 cases (1."	( Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Kim, CS; Kim, CW; Kim, HY; Lee, CD; Lee, HJ; Llamoso, C; Yu, K, 2018)	0.48
" Death, acute pancreatitis, lactic acidosis and kidney function impairment were considered as major adverse events."	( Efficacy and safety of long-term entecavir therapy in a European population. Belci, P; Collo, A; Durazzo, M; Fagoonee, S; Gariglio, V; Loreti, L; Magistroni, P; Parise, R, 2018)	0.48
" No major adverse events were recorded."	( Efficacy and safety of long-term entecavir therapy in a European population. Belci, P; Collo, A; Durazzo, M; Fagoonee, S; Gariglio, V; Loreti, L; Magistroni, P; Parise, R, 2018)	0.48
" Finally, ETV is a safe drug, substantially free of major side effects."	( Efficacy and safety of long-term entecavir therapy in a European population. Belci, P; Collo, A; Durazzo, M; Fagoonee, S; Gariglio, V; Loreti, L; Magistroni, P; Parise, R, 2018)	0.48
" None of our patients reported NUCs-related complications or adverse effects."	( Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety. Akroof, K; Darweesh, SK; ElLatif, ZA; Gad, AA, 2019)	0.51
"ETV and other NUCs were effective and safe as a long-term prophylaxis of HBV recurrence after LTx, leading to a good graft function."	( Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety. Akroof, K; Darweesh, SK; ElLatif, ZA; Gad, AA, 2019)	0.51
" Entecavir and tenofovir were safe and well tolerated, while treatment with telbivudine was associated with development of myopathy in 13% of cases."	( Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Abdurakhmanov, DT; Ibragimov, EK; Moiseev, SV; Nikulkina, EN; Odintsov, AV; Panevkina, SV; Rozina, TP; Tanaschuk, EL, 2019)	0.51
" However, less attention has been put on their adverse events."	( Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019)	0.51
" Poisson-prior-based Bayesian NMA was performed to synthesize both direct and indirect evidence with reporting hazard ratios (HRs) and 95% credible intervals (CrIs) for serious adverse events (SAEs) and hepatic/renal impairments."	( Bayesian Network Meta-Analysis for Assessing Adverse Effects of Anti-hepatitis B Drugs. Ji, J; Jia, Y; Shen, Y; Xun, P; Zhou, J, 2019)	0.51
"The combination of hepatitis B virus RNA and hepatitis B core-related antigen performed satisfactorily in predicting clinical relapse and hepatitis B surface antigen loss after stopping nucleos(t)ide analogue treatment among noncirrhotic hepatitis B e antigen-positive patients with chronic hepatitis B and could be used to guide safe discontinuation."	( Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B. Bai, X; Chen, X; Fan, R; Hou, J; Niu, J; Peng, J; Ren, H; Sheng, J; Sun, J; Tan, D; Tang, H; Wang, H; Wang, M; Wu, Y; Xie, Q; Xu, M; Zhou, B, 2020)	0.56
" In addition, the number of adverse events was significantly reduced by ETV plus Tα1, compared to ETV alone (RR = 0."	( The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. Chen, JH; Hou, M; Li, B; Li, C; Peng, D; Wang, XF; Xing, HY, 2020)	0.56
"ETV plus Tα1 might lead to a higher clinical response and a lower comprehensive adverse reaction rate in HBV-related patients with cirrhosis, compared to ETV alone."	( The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. Chen, JH; Hou, M; Li, B; Li, C; Peng, D; Wang, XF; Xing, HY, 2020)	0.56
" The treatment using NAs was well-tolerated and there was no serious drug-related adverse event reported."	( Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B. Chen, T; Chen, Y; Fu, M; Fu, S; Gao, Z; He, Y; Hu, C; Li, J; Liu, J; Yan, T; Yang, Y; Zhang, R; Zhao, Y; Zhou, M, 2021)	0.62
"ETV, TDF, and TAF were safe antiviral agents and showed similar antiviral effect for CHB at 48 weeks."	( Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Jeong, S; Kim, HI; Shin, HP, 2022)	0.72
" The safety endpoints were the incidence of HBV virologic breakthrough and adverse events."	( The efficacy and safety of tacrolimus and entecavir combination therapy in the treatment of hepatitis B virus-associated glomerulonephritis: a multi-center, placebo controlled, and single-blind randomized trial. Hou, JH; Li, RZ; Li, ZL; Liu, DL; Xie, BY; Xie, XF; Xu, LX; Ye, ZM; Zhang, L; Zhang, WH, 2022)	0.72
" 10 patients occurred adverse reaction, most of them were mild, and all recovered or achieved remission."	( Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial. Huang, JQ; Jiang, XG; Li, XD; Liang, J; Liu, CH; Liu, P; Lv, YH; Sun, KW; Xie, Q; Xing, HC; Zhang, B; Zhang, KJ; Zhang, W; Zhang, Y; Zhang, YX; Zhao, ZM; Zhu, CW; Zong, YL, 2022)	0.72
"The combination therapy of FZHY, TCM granules and ETV could regress the liver fibrosis in the patients with HBV cirrhosis, who experienced 2 years of ETV treatment, and it is safe and well tolerated."	( Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial. Huang, JQ; Jiang, XG; Li, XD; Liang, J; Liu, CH; Liu, P; Lv, YH; Sun, KW; Xie, Q; Xing, HC; Zhang, B; Zhang, KJ; Zhang, W; Zhang, Y; Zhang, YX; Zhao, ZM; Zhu, CW; Zong, YL, 2022)	0.72
"This retrospective study explored whether entecavir is effective and safe for the treatment of HBV-GN with renal insufficiency."	( Efficacy and safety of entecavir for hepatitis B virus-associated glomerulonephritis with renal insufficiency. Bu, Q; Jiang, W; Xu, L; Xu, T; Xu, Y; Yang, C; Yu, Y; Zhang, W; Zhao, L, 2023)	0.91
" However, greater adverse effects on renal function were observed for TDF than ETV at 60 months compared to 12 months."	( Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)	0.91
"Long-term administration of TDF has resulted in stronger adverse effects than TAF and ETV in regard to both renal function and bone tissue in CHB patients."	( Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis. Liu, S; Liu, Z; Ma, X; Xin, Y; Zhao, Z, 2023)	0.91

Excerpt	Reference	Relevance
" Blood and urine samples were collected for pharmacokinetic analyses."	( Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. Bifano, M; Grasela, DM; LaCreta, F; Olsen, S; Smith, RA; Yan, JH; Zhang, D, 2006)	0.33
" Pharmacokinetic assessments were performed on days 4 and 24 for adefovir and on days 14 and 24 for entecavir."	( Absence of a pharmacokinetic interaction between entecavir and adefovir. Bifano, M; Grasela, DM; LaCreta, F; Smith, RA; Yan, JH; Zhang, D, 2007)	0.34
" Blood samples were collected and determined for pharmacokinetic analyses."	( Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers. Davey, AK; He, Y; Liu, F; Wang, JP; Yang, J; Zhang, QH, 2010)	0.36
" The objectives were to identify significant and clinically meaningful covariate effects on entecavir population pharmacokinetic parameters and assess whether differences exist between Japanese and non-Japanese patients."	( Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. Bifano, M; Hiraoka, M; Ishikawa, H; Pfister, M; Roy, A; Sakurai, T; Seriu, T; Yoshitsugu, H, 2011)	0.37
"Pretreatment with glycyrrhizin resulted in no significant alterations in the main pharmacokinetic parameters of ETV in the short-term and long-term administration experiments."	( Effect of diammonium glycyrrhizinate on entecavir pharmacokinetics in rats. Hao, HP; Hao, K; Li, FY; Wang, GJ; Yan, TT, 2013)	0.39
" The validated method was used for a pharmacokinetic study of entecavir in rats and dogs."	( A validated method for quantifying entecavir in biological matrices and its application in a pharmacokinetic study in rats and dogs. Huang, X; Jiang, ZZ; Tang, WW; Xiao, Y; Zhang, LY; Zhang, ZJ, 2013)	0.39
"Data from recent clinical trials were used to develop a population pharmacokinetic (PPK) model, which allowed us to estimate entecavir exposures in children and compare them to ranges known to be efficacious in adults."	( Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations. Bertz, R; Bifano, M; Chan, P; LaCreta, F; Mould, DR; Reynolds, L; Tarif, MA, 2016)	0.43
" The ETV-HQD group exhibited a decrease in the maximum plasma concentration (Cmax), and a delay in time to achieve Cmax (tmax) following single- and multi-dose administrations, and decreased area under the concentration- time curve (AUC0–t) following single dosing."	( [Effect of Huangqi decoction on entecavir pharmacokinetics in rat plasma]. Li, YY; Liu, P; Ma, YM; Zeng, JK; Zhang, H; Zhang, XY, 2016)	0.43

Excerpt	Reference	Relevance
"This study was designed to test the efficacy of antiviral treatment with entecavir (ETV) in combination with DNA vaccines expressing duck hepatitis B virus (DHBV) antigens as a therapy for persistent DHBV infection in ducks."	( Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. Colonno, RJ; Foster, WK; Jilbert, AR; Kotlarski, I; Marion, PL; Miller, DS, 2003)	0.32
" These findings suggest that ETV treatment combined with post-exposure "prime-boost" vaccination induced immune responses that eliminated DHBV-infected hepatocytes and prevented the development of persistent DHBV infection."	( Antiviral therapy with entecavir combined with post-exposure "prime-boost" vaccination eliminates duck hepatitis B virus-infected hepatocytes and prevents the development of persistent infection. Boyle, D; Colonno, R; Feng, F; Jilbert, AR; Kotlarski, I; Miller, DS; Reaiche, GY, 2008)	0.35
" We investigated the activity of clevudine (CLV) in combination with other nucleoside/nucleotide analogues to determine if these combinations were compatible in vitro."	( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010)	0.36
"Using the HepAD38 cell line, which expresses wild-type HBV, and a real-time PCR assay, we tested the anti-HBV activity of CLV in combination with entecavir, lamivudine, adefovir, tenofovir and telbivudine (TBV)."	( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010)	0.36
"When CLV was combined with entecavir, lamivudine, adefovir or tenofovir, a synergistic antiviral effect was observed; however, the combination of CLV and TBV gave an antagonistic antiviral response."	( Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors. Bao, H; Furman, PA; Korba, B; Micolochick Steuer, HM; Murakami, E; Niu, C; Tolstykh, T, 2010)	0.36
"Entecavir combined with adefovir is an effective rescue therapy in CHB patients after failure of treatment with nucleoside analogs."	( [Safety and efficacy of Entecavir combined with Adefovir in patients with chronic hepatitis B who fail to respond to nucleoside analog treatment]. Guo, YB; Hou, JL; Peng, J; Sun, J; Wang, ZH; Yan, L; Yang, J; Zhou, B, 2011)	0.37
" We aimed to elucidate whether entecavir was a substrate of OAT1, OAT3, OCT, and PEPT1 and to investigate the targets of drug-drug interactions between entecavir and JBP485."	( OAT1 and OAT3: targets of drug-drug interaction between entecavir and JBP485. Kaku, T; Liu, K; Liu, Q; Ma, X; Meng, Q; Peng, J; Sun, H; Wang, C; Xu, Q, 2013)	0.39
"Inoculation with different WHV doses had a strong influence on the course of WHV infection; NA alone or in combination with a DNA vaccine completely prevented viremia after a high dose of WHV inoculation in Chinese woodchucks and induced partial or complete protective immunity, respectively."	( Nucleoside analogues alone or combined with vaccination prevent hepadnavirus viremia and induce protective immunity: alternative strategy for hepatitis B virus post-exposure prophylaxis. Fan, W; Huang, S; Lu, M; Song, Z; Tao, Y; Wang, B; Wang, H; Wang, J; Wang, Z; Yang, D; Zhu, B; Zhu, Z, 2014)	0.4
"NA-based PEP strategies (NA alone or in combination with vaccine) may be an alternative of HBV PEP, especially in those living in the remote and rural areas of the developing countries and the non-responders to the current vaccine, and may be valuable in the PEP of HBV and HIV co-infection after occupational and non-occupational exposure."	( Nucleoside analogues alone or combined with vaccination prevent hepadnavirus viremia and induce protective immunity: alternative strategy for hepatitis B virus post-exposure prophylaxis. Fan, W; Huang, S; Lu, M; Song, Z; Tao, Y; Wang, B; Wang, H; Wang, J; Wang, Z; Yang, D; Zhu, B; Zhu, Z, 2014)	0.4
" The influence of furin suppression on HBV replication and the effect of CMK combined with nucleoside analog entecavir (ETV) on HBV replication and HBeAg secretion was investigated in HepG2."	( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014)	0.4
" Moreover, the viral replication-enhancing effect of CMK was abrogated by ETV and ETV combined with CMK reduced HBV replication and HBeAg secretion simultaneously."	( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014)	0.4
" Nucleotide/nucleoside analogs combined with furin inhibitors may be a potential easy way to realize the dual goals of the antiviral therapy for chronic hepatitis B in the future."	( Entecavir combined with furin inhibitor simultaneously reduces hepatitis B virus replication and e antigen secretion. Gu, L; Li, DM; Peng, XM; Yang, HY; Zheng, NQ, 2014)	0.4
" This study suggests the proof-of-concept that the lower dose of NA in combination with other NA might be the theoretical option for rescue combination therapy in patients with CHB who had failed on prior multiple NA treatments in order to reduce systemic exposure and possible side effects of NA."	( Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. Cho, Y; Kim, YJ; Lee, HS; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
"Infusion of two high doses of HBIG during surgery in combination with entecavir significantly prevented HBV recurrence and improved the 3-year survival after liver transplantation."	( A new scheme with infusion of hepatitis B immunoglobulin combined with entecavir for prophylaxis of hepatitis B virus recurrence among liver transplant recipients. Bai, JH; Chen, G; Gan, XM; Hu, ZQ; Li, L; Liu, H; Liu, QY; Ma, LJ; Wang, DD; Wang, F; Zhao, YP, 2015)	0.42
" We evaluated the therapeutic efficacy of HBV-pulsed DCs in combination with the antiviral drug entecavir in patients with CHB."	( Efficacy of HBV-pulsed DCs in combination with entecavir in patients with chronic hepatitis B infection. Jiang, YL; Li, XH; Liu, XL; Pan, XN; Shen, JK; Wei, KP; Wei, MJ; Zhang, CY; Zhang, XM, 2015)	0.42
" We determined the in vivo antiviral efficacy and effects on innate and endoplasmic reticulum (ER) stress responses of NVR3-778 alone or in combination with pegylated interferon alpha (peg-IFN) and compared with entecavir."	( Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection. Allweiss, L; Dandri, M; Flores, OA; Hartman, G; Klumpp, K; Lam, AM; Lütgehetmann, M; Shimada, T; Volz, T, 2018)	0.48
"The aim of this study was to investigate the reactivation of the hepatitis B virus (HBV) following transarterial chemoembolization (TACE) in primary hepatocellular carcinoma (HCC) patients with HBV-DNA negative and to evaluate the effects of TACE combined with antiviral therapy."	( Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative. Jia, Z; Jiang, G; Ni, C; Wang, K; Zhu, X, 2018)	0.48
" However, the development of HBVr combined with NS after allo-HSCT is uncommon."	( Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation. Li, XD; Long, B; Sun, YL; Wang, XZ; Zhang, JW; Zhang, XZ, 2019)	0.51
" However, she developed HBVr combined with nephrotic syndrome (NS) 16 months after HSCT."	( Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation. Li, XD; Long, B; Sun, YL; Wang, XZ; Zhang, JW; Zhang, XZ, 2019)	0.51
"Entecavir combined with immunosuppression has efficacy in the treatment of HBVr combined with NS after allo-HSCT, but long course of treatment is needed."	( Reactivation of resolved hepatitis B virus infection combined with nephrotic syndrome in a patient after allogeneic haematopoietic stem cell transplantation. Li, XD; Long, B; Sun, YL; Wang, XZ; Zhang, JW; Zhang, XZ, 2019)	0.51
"The network meta-analysis (NMA) is to evaluate whether entecavir combined with Chinese patent medicine, such as "fuzhenghuayu capsules," "anluohuaxian pills," "fufangbiejiaruangan tablets," shows superior efficiency compared with entecavir alone for the treatment of chronic HBV-related liver fibrosis or cirrhosis."	( The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies. Hong, J; Huang, H; Huo, S; Song, Y; Wang, S; Zhao, J; Zuo, J, 2019)	0.51
" We will search PubMed, EMbase, Medline, Cochrane, China Network Knowledge Infrastructure (CNKI), and Wanfang for randomized controlled trials (RCTs) or "prospective cohort studies" of "fuzhenghuayu capsules," "anluohuaxian pills," "fufangbiejiaruangan tablets" respectively combined with entecavir in the treatment of chronic HBV-related liver fibrosis or cirrhosis from their inception to September 30, 2018."	( The efficacy of Chinese patent medicine combined with entecavir for the treatment of chronic HBV-related liver fibrosis or cirrhosis: Protocol for a systematic review and meta-analysis of randomized controlled trials or prospective cohort studies. Hong, J; Huang, H; Huo, S; Song, Y; Wang, S; Zhao, J; Zuo, J, 2019)	0.51
"To investigate the effects of radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) and antiviral therapy on the prognosis and quality of life in primary chronic hepatitis B virus (HBV)-related liver cancer."	( Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer. Cheng, Y; Fan, J; Lu, B; Wang, X; Yu, L; Zhong, L; Zhu, L, )	0.13
" The patients in the control group were treated with RFA combined with TACE, while those in the observation group were additionally treated with entecavir."	( Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer. Cheng, Y; Fan, J; Lu, B; Wang, X; Yu, L; Zhong, L; Zhu, L, )	0.13
"The RFA combined with TACE and regular antiviral therapy for HBV-related liver cancer is of significance in reducing the HBV-DNA load and tumor markers, improving the liver function, promoting the overall clinical therapeutic effect and prolonging the survival of patients."	( Effects of radiofrequency ablation combined with transarterial chemoembolization and antiviral therapy on the prognosis and quality of life in primary chronic HBV-related liver cancer. Cheng, Y; Fan, J; Lu, B; Wang, X; Yu, L; Zhong, L; Zhu, L, )	0.13
" Traditional Chinese medicine combined with antiviral therapy has become the first choice for clinical treatment of hepatitis b Cirrhosis."	( Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis. Cao, N; Feng, X; Li, G; Shi, J; Wang, B; Wang, L; Yang, Y; Zhang, T; Zheng, X, 2019)	0.51
" Randomized controlled trials (RCTs) on Biejiajian Pill combined with Entecavir and Entecavir alone against Compensatory period of hepatitis b cirrhosis will be included; inclusion and exclusion criteria will be used to screen the trials."	( Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis. Cao, N; Feng, X; Li, G; Shi, J; Wang, B; Wang, L; Yang, Y; Zhang, T; Zheng, X, 2019)	0.51
"This study protocol will be used to evaluate the efficacy and safety of Biejia Pill in combination with entecavir in the treatment of Compensatory period of hepatitis b cirrhosis, as well as the adjuvant treatment of Biejia Pill in combination."	( Meta-analysis of influences of Biejiajian Pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: Protocol of systematic review and meta-analysis. Cao, N; Feng, X; Li, G; Shi, J; Wang, B; Wang, L; Yang, Y; Zhang, T; Zheng, X, 2019)	0.51
"Randomized controlled trials (RCTs) of KS combined with ETV for CHB will be identified from PubMed, EMBASE, Web of Science, The Cochrane Library, Chinese Biomedical Database, China National Knowledge Infrastructure, Chongqing VIP, Wangfang Data."	( Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis. Jin, Y; Wang, Y; Xiao, X; Zhang, J; Zhang, Q, 2020)	0.56
"A high-quality synthesis of current evidence on the efficacy and safety of KS combined with ETV for CHB will be provided in this study."	( Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis. Jin, Y; Wang, Y; Xiao, X; Zhang, J; Zhang, Q, 2020)	0.56
"This systematic review will aim to evaluate the efficacy and safety of KS combined with ETV for CHB."	( Kushenin combined with entecavir for chronic hepatitis B: A protocol for a systematic review and meta-analysis. Jin, Y; Wang, Y; Xiao, X; Zhang, J; Zhang, Q, 2020)	0.56
"A 55-year-old MM patient with a family history of MM, who was also a chronic HBV carrier, achieved HBV clearance after treatment with a bortezomib-based regimen in combination with anti-HBV drugs."	( Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report. Li, X; Liang, Y; Tong, J; Wang, W; Xu, Y; Zhang, X, 2020)	0.56
"This is the first case of MM with HBV clearance after receiving a bortezomib-based regimen combined with anti-HBV drug."	( Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report. Li, X; Liang, Y; Tong, J; Wang, W; Xu, Y; Zhang, X, 2020)	0.56
" The present study evaluated long-term AIC649 treatment in combination with Entecavir for potency and safety in woodchucks."	( Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B. Huang, X; Kallakury, BV; Korolowicz, KE; Leng, X; Li, B; Menne, S; Suresh, M; Tucker, RD; Yon, C, 2021)	0.62
"The objective of this study was to assess whether entecavir (ETV) in combination with interferon-α (IFN-α) could reduce hepatocellular cancer (HCC) and extrahepatic cancers (EHCs) in patients with chronic hepatitis B (CHB)."	( Entecavir combined with interferon-α Is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Chen, Y; Cheng, K; Duan, X; Duan, Z; Liao, W; Sun, Y; Wang, L; Wang, X; Xu, M; Zhao, X, 2022)	0.72
"The cohort consisted of 4194 patients with CHB treated with ETV combined with IFN-α or ETV monotherapy at a tertiary hospital in Beijing, China, from January 2009 to December 2017."	( Entecavir combined with interferon-α Is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Chen, Y; Cheng, K; Duan, X; Duan, Z; Liao, W; Sun, Y; Wang, L; Wang, X; Xu, M; Zhao, X, 2022)	0.72
"0854) were observed in the group receiving ETV combined with IFN-α in comparison with the ETV monotherapy group."	( Entecavir combined with interferon-α Is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Chen, Y; Cheng, K; Duan, X; Duan, Z; Liao, W; Sun, Y; Wang, L; Wang, X; Xu, M; Zhao, X, 2022)	0.72
"ETV combined with IFN-α therapy is superior to ETV monotherapy in reducing the risk of HCC and EHCs for patients with CHB."	( Entecavir combined with interferon-α Is superior to entecavir monotherapy in reducing hepatic and extrahepatic cancer in patients with chronic hepatitis B. Chen, Y; Cheng, K; Duan, X; Duan, Z; Liao, W; Sun, Y; Wang, L; Wang, X; Xu, M; Zhao, X, 2022)	0.72
" Renal excretion played an important role in the elimination of Y101 and its metabolites, M8 and M9, in healthy Chinese subjects, although the molecular mechanisms of renal excretion and potential drug-drug interactions (DDIs) remain unclear."	( OAT3 Participates in Drug-Drug Interaction between Bentysrepinine and Entecavir through Interactions with M8-A Metabolite of Bentysrepinine-In Rats and Humans In Vitro. Dong, S; Fan, H; Huo, X; Li, C; Li, W; Liu, J; Peng, Y; Yang, F; Yuan, Y; Zhang, A; Zhang, N; Zheng, J; Zhou, S, 2023)	0.91
" The aim of this study was to evaluate the effect of nucleoside analogs entecavir combined with short-term HBIG in preventing HBV recurrence after LT."	( Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients. Guo, Y; Li, X; Liu, L; Nashan, B; Qi, C; Qin, J; Wang, J; Wang, N; Wu, W; Xu, Z; Yuan, X; Zheng, H; Zhu, Z, 2023)	0.91
" All patients received entecavir treatment combined with HBIG for the prevention of hepatitis B recurrence, and HBIG treatment was withdrawn within 1 month."	( Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients. Guo, Y; Li, X; Liu, L; Nashan, B; Qi, C; Qin, J; Wang, J; Wang, N; Wu, W; Xu, Z; Yuan, X; Zheng, H; Zhu, Z, 2023)	0.91
"Entecavir combined with short-term HBIG can exert a good effect for the prevention of HBV reinfection post-LT."	( Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients. Guo, Y; Li, X; Liu, L; Nashan, B; Qi, C; Qin, J; Wang, J; Wang, N; Wu, W; Xu, Z; Yuan, X; Zheng, H; Zhu, Z, 2023)	0.91
"To evaluate the effects of Zhenggan Huayu decoction (, ZGHY) combined with entecavir (ETV) on the gut microbiota in patients with chronic hepatitis B (CHB) fibrosis."	( Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis. Daguo, Y; Fang, L; Jinzhen, LV; Wenlin, C; Yuncheng, Z, 2023)	0.91
"A total of 59 CHB-related fibrosis patients were enrolled and treated with ZGHY combined with ETV (ZGHY + ETV) and ETV alone."	( Effects of Zhenggan Huayu decoction combined with entecavir on gut microbiota in patients with chronic hepatitis B fibrosis. Daguo, Y; Fang, L; Jinzhen, LV; Wenlin, C; Yuncheng, Z, 2023)	0.91

Excerpt	Reference	Relevance
" The lead candidates, both 1a (PBHBV-001) and 3c (PBHBV-2-15), were well-tolerated in both normal and HBV-transgenic mice and exhibited acceptable pharmacokinetics and bioavailability in Sprague-Dawley rats."	( Design, synthesis, and biological evaluation of triazolo-pyrimidine derivatives as novel inhibitors of hepatitis B virus surface antigen (HBsAg) secretion. Block, TM; Clearfield, E; Cuconati, A; Goddard, C; Guo, H; Mills, C; Morrey, JD; Motter, NE; Xiao, T; Xu, X; Yu, W; Zhao, K, 2011)	0.37
" In particular, the (2S,4S)-4,4-difluoroproline substituted analogue 34a demonstrated high oral bioavailability and liver exposure and achieved over 2 log viral load reduction in a hydrodynamic injected (HDI) HBV mouse model."	( Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors. Chen, W; Guo, L; Huang, M; Jiang, M; Lin, X; Liu, H; Liu, Y; Mao, Y; Mayweg, AV; Qin, N; Qiu, H; Qiu, Z; Ren, S; Shen, F; Shen, HC; Shi, L; Tang, G; Wu, G; Wu, JZ; Wu, X; Xu, Z; Yang, G; Yang, W; Zhang, W; Zhang, Y; Zhong, S; Zhou, M; Zhou, X; Zhou, Z; Zhu, W, 2016)	0.43
"SB 9200, an orally bioavailable dinucleotide, activates the viral sensor proteins, retinoic acid-inducible gene 1 (RIG-I) and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) causing the induction of the interferon (IFN) signaling cascade for antiviral defense."	( Antiviral Efficacy and Host Immune Response Induction during Sequential Treatment with SB 9200 Followed by Entecavir in Woodchucks. Afdhal, N; Balarezo, M; Cleary, D; Gimi, R; Iyer, RP; Kallakury, BV; Korolowicz, KE; Menne, S; Padmanabhan, S; Sheri, A; Suresh, M; Tucker, RD; Yon, C, 2017)	0.46
" In particular, it demonstrated a good systemic exposure and high oral bioavailability and achieved a viral-load reduction greater than 2 log in a hydrodynamic-injected (HDI) HBV mouse model and has now been selected for further development."	( 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4. Chen, Y; Goldmann, S; Gu, B; Huang, J; Li, J; Liu, X; Luo, Z; Nie, B; Ren, Q; Wei, Y; Yan, G; Zhang, J; Zhang, Y; Zou, Z, 2018)	0.48
" The absorption rate and extent of EV after SC injection of 12."	( Design and in vivo evaluation of entecavir-3-palmitate microcrystals for subcutaneous sustained delivery. Choi, YW; Han, YT; Ho, MJ; Im, SH; Jang, SW; Kang, MJ; Kim, HJ; Lee, DR; Shin, CY; Yoon, JA, 2018)	0.48
" RG7834, a compound from the dihydroquinolizinone (DHQ) chemical series, is a first-in-class highly selective and orally bioavailable HBV inhibitor which can reduce both viral antigens and viral DNA with a novel mechanism of action."	( Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. Cheng, Z; Han, X; Javanbakht, H; Jiang, M; Liang, C; Liu, Y; Luangsay, S; Lv, W; Mayweg, AV; Shen, HC; Wang, J; Wang, M; Wang, Y; Wang, Z; Weikert, R; Xie, J; Yang, S; Yu, X; Zhou, C; Zhou, X, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" A clear dose-response relationship was observed for entecavir with the higher doses showing significantly greater viral suppression."	( Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Anderson, FH; Dehertogh, D; Lai, CL; Lao, J; Rosmawati, M; Thomas, N; Van Vlierberghe, H, 2002)	0.31
" Preemptive post-transplant lamivudine monotherapy is associated with progressively increasing HBV recurrence rates, but combined therapy with lamivudine and HBIG at relatively low dosage is currently the most effective approach in this setting, even in HBV-DNA-positive patients, who also receive lamivudine in the pretransplant period."	( Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Burroughs, AK; Papatheodoridis, GV; Sevastianos, V, 2003)	0.32
"5 mg as a better dosage for a further large scale clinical trial."	( [A study of the dosage and efficacy of entecavir for treating hepatitis B virus]. Lei, BJ; Wang, BE; Xu, DZ; Yao, GB; Zhang, DF; Zhou, XQ, 2005)	0.33
" There were no clinically meaningful differences in the incidence of any adverse events between the entecavir dosing and the placebo groups."	( [A study of the dosage and efficacy of entecavir for treating hepatitis B virus]. Lei, BJ; Wang, BE; Xu, DZ; Yao, GB; Zhang, DF; Zhou, XQ, 2005)	0.33
" Treatment of patients with lamivudine failure requires a higher dosage of entecavir and induces a significant decline in viraemia levels."	( Entecavir: a new treatment option for chronic hepatitis B. Zoulim, F, 2006)	0.33
" At steady state, the mean area under the plasma concentration-time curve over 1 dosing interval, increased approximately proportional to dose."	( Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. Bifano, M; Grasela, DM; LaCreta, F; Olsen, S; Smith, RA; Yan, JH; Zhang, D, 2006)	0.33
" Genotyping all additional ETV patients with PCR-detectable HBV DNA at Weeks 48, 96, or end of dosing identified seven additional patients with LVDr substitutions, including one with simultaneous emergence of LVDr/ETVr."	( Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Baldick, CJ; Colonno, RJ; Eggers, B; Fang, J; Hsu, M; Klesczewski, K; Levine, S; Mazzucco, C; Plym, M; Pokornowski, K; Rose, R; Tenney, DJ; Walsh, A; Yu, CF; Zhang, S, 2006)	0.33
"5 mg and 1 mg, respectively, with 33% of patients in each dosing group achieving <400 copies/mL."	( Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Imazeki, F; Kage, M; Katano, Y; Kumada, H; Moriyama, M; Omata, M; Sata, M; Seriu, T; Suzuki, F; Toyoda, J, 2008)	0.35
" To attain a better antiviral response the dosage of entecavir was increased to 2mg daily in two patients, resulting in further viral load decline for both of them."	( Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009)	0.35
"Entecavir monotherapy dosed at 1mg resulted in a slow reduction of viral load in both lamivudine-experienced and -naïve patients with persistently high HBV DNA during adefovir therapy."	( Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. de Man, RA; Janssen, HL; Pas, SD; Reijnders, JG; Schutten, M, 2009)	0.35
" Developing optimal treatment regimens requires understanding how to best measure anti-HIV activity in vitro and how drug dose-response curves generated in vitro correlate with in-vivo efficacy."	( New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. McMahon, MA; Shen, L; Siliciano, RF, 2009)	0.35
" Recent studies using a single-round infectivity assay have shown that a previously neglected parameter, the dose-response curve slope, is an extremely important determinant of antiviral activity."	( New approaches for quantitating the inhibition of HIV-1 replication by antiviral drugs in vitro and in vivo. McMahon, MA; Shen, L; Siliciano, RF, 2009)	0.35
"5 mg orally, daily) or lamivudine (100 mg orally, daily) together with a long-term low dosage of HBIG to prevent hepatitis B recurrence after transplantation."	( The role of entecavir in preventing hepatitis B recurrence after liver transplantation. Chen, XS; Han, LZ; Luo, Y; Qiu, DK; Shen, CH; Wang, SY; Wang, X; Xi, ZF; Xia, Q; Xin, TY; Zhang, JJ, 2009)	0.35
"An RP-HPLC method was validated for the determination of entecavir in tablet dosage form."	( Validation of a stability-indicating RP-HPLC method for the determination of entecavir in tablet dosage form. da Silva, LM; Dalmora, SL; Nogueira, DR; Sangoi, Mda S, )	0.13
"9999), and was applied for the analysis of entecavir in tablet dosage forms."	( Development and validation of a stability-indicating capillary zone electrophoretic method for the assessment of entecavir and its correlation with liquid chromatographic methods. D'Avila, FB; Dalmora, SL; Leal, DP; Nogueira, DR; Souto, RB, 2011)	0.37
" Entecavir provides sustained viral suppression and histological benefit with minimal resistance during long-term treatment of chronic hepatitis B, it is well-tolerable and has good safety profile, simple dosing and simple monitoring requirements."	( [Long-term therapy with nucleoside analog entecavir (baraclude) in patients with chronic hepatitis B]. Halota, W; Pawłowska, M, 2011)	0.37
" Entecavir was given at a dosage of 1 mg/d for 1 year."	( Entecavir treatment of chronic hepatitis D. Bozdayi, AM; Idilman, R; Kabaçam, G; Karatayli, E; Karatayli, SC; Onder, FO; Savas, B; Seven, G; Yakut, M; Yurdaydin, C, 2012)	0.38
"NAs are cleared by kidneys and their dosage should be adjusted in patients with creatinine clearance <50 mL/min."	( Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Cholongitas, E; Papatheodoridis, G; Pipili, C, 2014)	0.4
" Antiviral treatments were withdrawn in patients who met all of the following 7 criteria: (i) no clinical and histologic evidence of cirrhosis, (ii) normal liver biochemistry, (iii) negative for both HBV DNA and hepatitis B envelope antigen (HBeAg), (iv) no resistance to antiviral agent, (v) antiviral therapy > 9 months, (vi) maintenance dosage of immunosuppressant for > 3 months, and (vii) no history of acute rejection during recent 6 months."	( Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection. Cho, JH; Choi, JY; Huh, S; Kang, YJ; Kim, CD; Kim, HK; Kim, JS; Kim, YL; Kwon, O; Lim, JH; Park, GY; Park, SH, 2014)	0.4
"To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year."	( Is increasing the dose of Entecavir effective in partial virological responders? Akdogan, RA; Cumhur Cure, M; Cure, E; Erturk, A; Ozturk, C; Parlak, E, 2014)	0.4
"Using non-linear regression models, dose-response curves of cloned HBV strains from patients pre-treated with RT inhibitors were established in human hepatoma cell lines after transfection with HBV genomes containing HBV polymerase genes from patient isolates."	( Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine. Geipel, A; Gerlich, WH; Glebe, D; Kaiser, R; Neumann-Fraune, M; Niekamp, H; Protzer, U; Seiz, PL; Zhang, K, 2015)	0.42
"The entecavir dose-response curve of lamivudine-resistant HBV RT mutants rtM204 for the replication of HBV decreased less than expected with increasing drug dose."	( Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine. Geipel, A; Gerlich, WH; Glebe, D; Kaiser, R; Neumann-Fraune, M; Niekamp, H; Protzer, U; Seiz, PL; Zhang, K, 2015)	0.42
"Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of NAs, and combination therapy of NA and MRP inhibitors could reduce the dosage for long-term NA use."	( Multidrug resistance protein 4 is a critical protein associated with the antiviral efficacy of nucleos(t)ide analogues. Chen, Q; Liu, W; Liu, Y; Lu, M; Song, H; Wang, B; Xu, C; Xu, D; Yang, D; Zhang, W; Zheng, X, 2016)	0.43
"To develop simplified entecavir dosing recommendations for young children infected with CHB."	( Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations. Bertz, R; Bifano, M; Chan, P; LaCreta, F; Mould, DR; Reynolds, L; Tarif, MA, 2016)	0.43
"Model-estimated, steady-state entecavir area under the concentration-time curve, in both the original (15 weight groups) and simplified (eight weight groups) pediatric dosing regimens, provided entecavir exposures consistent with those observed to be efficacious in adults, and resulted in the simplified dose algorithm for pediatric patients that is approved for the current entecavir label."	( Using Population Pharmacokinetic and Pharmacodynamic Analyses of Entecavir in Pediatric Subjects to Simplify Dosing Recommendations. Bertz, R; Bifano, M; Chan, P; LaCreta, F; Mould, DR; Reynolds, L; Tarif, MA, 2016)	0.43
" The virologic response was determined by the dosage of serum HBV-DNA, HBsAg, HBeAg, anti-HBs and anti-HBe antibodies."	( Efficacy and safety of long-term entecavir therapy in a European population. Belci, P; Collo, A; Durazzo, M; Fagoonee, S; Gariglio, V; Loreti, L; Magistroni, P; Parise, R, 2018)	0.48
" The dose-response analyses of adherence rates showed that the risk of LREs increased progressively as medication adherence declined."	( Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. Jung, SW; Lee, BU; Lee, SB; Park, BR; Park, EJ; Park, NH; Shin, JW, 2018)	0.48
" The sirolimus dosage was increased to 2 mg daily without causing HBV reactivation."	( Successful Sirolimus Treatment of Lymphangioleiomyomatosis in a Hepatitis B Virus Carrier. Akira, M; Arai, T; Hirose, M; Inoue, Y; Kasai, T; Kitaichi, M; Sonobe, S; Sugimoto, C; Tanimoto, Y, 2019)	0.51
" The concentration of ETV in the liver was not obviously altered during pregnancy, which indicates that dosage adjustment in pregnancy is not necessary."	( Roles of organic anion transporter 2 and equilibrative nucleoside transporter 1 in hepatic disposition and antiviral activity of entecavir during non-pregnancy and pregnancy. Bai, M; Jiang, H; Jiang, T; Lin, N; Lu, S; Ma, Z; Sun, D; Zeng, S; Zhou, H, 2019)	0.51
" Because 70% of orally dosed ETV is eliminated by kidney, the effects of estradiol (E2) and progesterone (P4), 2 important hormones during pregnancy, on ETV-related renal transporters were investigated."	( Pregnancy Impacts Entecavir Pharmacokinetics but Does Not Alter Its Renal Excretion. Jiang, H; Jiang, T; Lin, N; Lu, S; Ma, Z; Wang, W; Yang, X; Zeng, S; Zhou, H, 2020)	0.56

Role	Description
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.
antiviral drug	A substance used in the prophylaxis or therapy of virus diseases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
2-aminopurines	Any aminopurine having the amino substituent at the 2-position.
oxopurine
primary alcohol	A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.
secondary alcohol	A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
benzamides
N-acylpiperidine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
TDP1 protein	Homo sapiens (human)	Potency	0.0068	0.0008	11.3822	44.6684	AID686978; AID686979
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	39.8107	0.0096	10.5250	35.4813	AID1479145
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	26.8370	0.0123	7.9835	43.2770	AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	12.9007	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
cytochrome P450 2D6	Homo sapiens (human)	Potency	37.9083	0.0010	8.3798	61.1304	AID1645840
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
Muscarinic acetylcholine receptor M2	Homo sapiens (human)	Ki	0.0720	0.0000	0.6902	10.0000	AID1915119
Muscarinic acetylcholine receptor M4	Homo sapiens (human)	Ki	0.4000	0.0000	0.7951	9.1201	AID1915121
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	IC50 (µMol)	3.5000	0.0000	1.4039	10.0000	AID771606
Muscarinic acetylcholine receptor M1	Homo sapiens (human)	Ki	0.0970	0.0000	0.5972	9.1201	AID1915118
Alpha-2C adrenergic receptor	Homo sapiens (human)	Ki	0.8600	0.0003	0.4834	10.0000	AID1915123
Muscarinic acetylcholine receptor M3	Homo sapiens (human)	Ki	0.8900	0.0000	0.5405	7.7600	AID1915120
Lysine-specific demethylase 5A	Homo sapiens (human)	IC50 (µMol)	20.0000	0.1300	2.3747	10.0000	AID1077871; AID771611
MBT domain-containing protein 1	Homo sapiens (human)	IC50 (µMol)	43.5000	9.0000	9.0000	9.0000	AID1077875; AID771615
Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)	IC50 (µMol)	0.1354	0.0240	1.4096	4.7000	AID1077877; AID1912836; AID1913327; AID771620; AID771621
Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)	IC50 (µMol)	5.6000	0.0980	4.2996	8.9000	AID1077876; AID771619
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Capsid protein	Hepatitis B virus	EC50 (µMol)	5.0001	0.0002	0.2603	0.8194	AID1363957; AID1377846
Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)	Kd	0.1200	0.1200	0.1200	0.1200	AID1578927; AID1915126; AID771609
Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)	Kd	9.4000	5.0000	8.1333	10.0000	AID771608
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Chromobox protein homolog 7	Homo sapiens (human)
chromatin organization	Chromobox protein homolog 7	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of heart contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
response to virus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
cell surface receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
positive regulation of monoatomic ion transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
neuromuscular synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of locomotion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cognition	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of postsynaptic membrane potential	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of glial cell proliferation	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
positive regulation of intracellular protein transport	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
regulation of smooth muscle contraction	Alpha-2C adrenergic receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
cell-cell signaling	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of norepinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
regulation of vasoconstriction	Alpha-2C adrenergic receptor	Homo sapiens (human)
platelet activation	Alpha-2C adrenergic receptor	Homo sapiens (human)
activation of protein kinase B activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of epinephrine secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
receptor transactivation	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of MAPK cascade	Alpha-2C adrenergic receptor	Homo sapiens (human)
positive regulation of neuron differentiation	Alpha-2C adrenergic receptor	Homo sapiens (human)
adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathway	Alpha-2C adrenergic receptor	Homo sapiens (human)
negative regulation of insulin secretion	Alpha-2C adrenergic receptor	Homo sapiens (human)
calcium-mediated signaling	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signal transduction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synaptic transmission, cholinergic	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nervous system development	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of insulin secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein modification process	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
positive regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
saliva secretion	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
ligand-gated ion channel signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
regulation of smooth muscle contraction	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
chemical synaptic transmission	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Lysine-specific demethylase 5A	Homo sapiens (human)
circadian regulation of gene expression	Lysine-specific demethylase 5A	Homo sapiens (human)
positive regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-binding transcription factor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
facultative heterochromatin formation	Lysine-specific demethylase 5A	Homo sapiens (human)
regulation of DNA-templated transcription	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin remodeling	Lysine-specific demethylase 5A	Homo sapiens (human)
double-strand break repair via homologous recombination	MBT domain-containing protein 1	Homo sapiens (human)
chromatin organization	MBT domain-containing protein 1	Homo sapiens (human)
regulation of apoptotic process	MBT domain-containing protein 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	MBT domain-containing protein 1	Homo sapiens (human)
embryonic skeletal system development	MBT domain-containing protein 1	Homo sapiens (human)
regulation of cell cycle	MBT domain-containing protein 1	Homo sapiens (human)
positive regulation of double-strand break repair via homologous recombination	MBT domain-containing protein 1	Homo sapiens (human)
regulation of double-strand break repair	MBT domain-containing protein 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	MBT domain-containing protein 1	Homo sapiens (human)
DNA damage response	TP53-binding protein 1	Homo sapiens (human)
double-strand break repair via nonhomologous end joining	TP53-binding protein 1	Homo sapiens (human)
chromatin organization	TP53-binding protein 1	Homo sapiens (human)
DNA damage response	TP53-binding protein 1	Homo sapiens (human)
positive regulation of isotype switching	TP53-binding protein 1	Homo sapiens (human)
positive regulation of DNA-templated transcription	TP53-binding protein 1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	TP53-binding protein 1	Homo sapiens (human)
positive regulation of DNA-binding transcription factor activity	TP53-binding protein 1	Homo sapiens (human)
protein homooligomerization	TP53-binding protein 1	Homo sapiens (human)
cellular response to X-ray	TP53-binding protein 1	Homo sapiens (human)
double-strand break repair via classical nonhomologous end joining	TP53-binding protein 1	Homo sapiens (human)
protein localization to site of double-strand break	TP53-binding protein 1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	TP53-binding protein 1	Homo sapiens (human)
DNA damage checkpoint signaling	TP53-binding protein 1	Homo sapiens (human)
chromatin organization	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
chromatin organization	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
macrophage differentiation	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
granulocyte differentiation	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
erythrocyte maturation	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
regulation of DNA methylation-dependent heterochromatin formation	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
positive regulation of ubiquitin-dependent protein catabolic process	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
double-strand break repair via homologous recombination	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
ubiquitin-dependent protein catabolic process	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
DNA damage response	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
heterochromatin formation	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
homologous recombination	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
epigenetic regulation of gene expression	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylation	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
regulation of epithelial cell proliferation	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
positive regulation of protein metabolic process	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
protein autoubiquitination	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
mitotic spindle assembly	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
protein ubiquitination	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
autophagy	PHD finger protein 23	Homo sapiens (human)
positive regulation of protein ubiquitination	PHD finger protein 23	Homo sapiens (human)
negative regulation of autophagosome maturation	PHD finger protein 23	Homo sapiens (human)
negative regulation of autophagosome assembly	PHD finger protein 23	Homo sapiens (human)
chromatin organization	Scm-like with four MBT domains protein 1	Homo sapiens (human)
spermatogenesis	Scm-like with four MBT domains protein 1	Homo sapiens (human)
cell differentiation	Scm-like with four MBT domains protein 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Scm-like with four MBT domains protein 1	Homo sapiens (human)
negative regulation of muscle organ development	Scm-like with four MBT domains protein 1	Homo sapiens (human)
chromatin organization	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
regulation of mitotic nuclear division	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
hemopoiesis	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
heterochromatin formation	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
regulation of megakaryocyte differentiation	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
regulation of cell cycle	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	Chromobox protein homolog 7	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
arrestin family protein binding	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
alpha2-adrenergic receptor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
alpha-2A adrenergic receptor binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein homodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
protein heterodimerization activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
epinephrine binding	Alpha-2C adrenergic receptor	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Alpha-2C adrenergic receptor	Homo sapiens (human)
phosphatidylinositol phospholipase C activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
protein binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled acetylcholine receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
signaling receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
acetylcholine binding	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
G protein-coupled serotonin receptor activity	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
transcription cis-regulatory region binding	Lysine-specific demethylase 5A	Homo sapiens (human)
DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
transcription coactivator activity	Lysine-specific demethylase 5A	Homo sapiens (human)
enzyme inhibitor activity	Lysine-specific demethylase 5A	Homo sapiens (human)
protein binding	Lysine-specific demethylase 5A	Homo sapiens (human)
zinc ion binding	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin DNA binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
histone H3K4me/H3K4me2/H3K4me3 demethylase activity	Lysine-specific demethylase 5A	Homo sapiens (human)
methylated histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
histone binding	Lysine-specific demethylase 5A	Homo sapiens (human)
protein binding	MBT domain-containing protein 1	Homo sapiens (human)
zinc ion binding	MBT domain-containing protein 1	Homo sapiens (human)
methylated histone binding	MBT domain-containing protein 1	Homo sapiens (human)
NuA4 histone acetyltransferase complex binding	MBT domain-containing protein 1	Homo sapiens (human)
chromatin binding	MBT domain-containing protein 1	Homo sapiens (human)
p53 binding	TP53-binding protein 1	Homo sapiens (human)
damaged DNA binding	TP53-binding protein 1	Homo sapiens (human)
transcription coregulator activity	TP53-binding protein 1	Homo sapiens (human)
protein binding	TP53-binding protein 1	Homo sapiens (human)
methylated histone binding	TP53-binding protein 1	Homo sapiens (human)
telomeric DNA binding	TP53-binding protein 1	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	TP53-binding protein 1	Homo sapiens (human)
ubiquitin-modified histone reader activity	TP53-binding protein 1	Homo sapiens (human)
histone reader activity	TP53-binding protein 1	Homo sapiens (human)
histone binding	TP53-binding protein 1	Homo sapiens (human)
protein binding	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
zinc ion binding	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
histone binding	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
chromatin binding	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
chromatin binding	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
protein binding	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
zinc ion binding	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
identical protein binding	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
methylation-dependent protein binding	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
histone binding	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
nucleic acid binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
ubiquitin-protein transferase activity	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
protein binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
zinc ion binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
methyl-CpG binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
methylated histone binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
histone binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
identical protein binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
hemi-methylated DNA-binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
ubiquitin protein ligase activity	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
H3K9me3 modified histone binding	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
DNA damage sensor activity	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
histone H3 ubiquitin ligase activity	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
protein binding	PHD finger protein 23	Homo sapiens (human)
metal ion binding	PHD finger protein 23	Homo sapiens (human)
transcription corepressor activity	Scm-like with four MBT domains protein 1	Homo sapiens (human)
protein binding	Scm-like with four MBT domains protein 1	Homo sapiens (human)
histone binding	Scm-like with four MBT domains protein 1	Homo sapiens (human)
chromatin binding	Scm-like with four MBT domains protein 1	Homo sapiens (human)
chromatin binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
protein binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
zinc ion binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
nucleosome binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
SAM domain binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
methylated histone binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
histone binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
identical protein binding	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
nucleus	Chromobox protein homolog 7	Homo sapiens (human)
nucleoplasm	Chromobox protein homolog 7	Homo sapiens (human)
cytosol	Chromobox protein homolog 7	Homo sapiens (human)
chromatin	Chromobox protein homolog 7	Homo sapiens (human)
PcG protein complex	Chromobox protein homolog 7	Homo sapiens (human)
PRC1 complex	Chromobox protein homolog 7	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
clathrin-coated endocytic vesicle membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
asymmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
symmetric synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
neuronal cell body	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M2	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M4	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
presynaptic membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
axon terminus	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
postsynaptic density membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
glutamatergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cholinergic synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M1	Homo sapiens (human)
cytoplasm	Alpha-2C adrenergic receptor	Homo sapiens (human)
endosome	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
plasma membrane	Alpha-2C adrenergic receptor	Homo sapiens (human)
endoplasmic reticulum membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basal plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
basolateral plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
postsynaptic membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
synapse	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
plasma membrane	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
dendrite	Muscarinic acetylcholine receptor M3	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleoplasm	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleolus	Lysine-specific demethylase 5A	Homo sapiens (human)
nucleus	Lysine-specific demethylase 5A	Homo sapiens (human)
chromatin	Lysine-specific demethylase 5A	Homo sapiens (human)
site of double-strand break	MBT domain-containing protein 1	Homo sapiens (human)
nucleosome	MBT domain-containing protein 1	Homo sapiens (human)
NuA4 histone acetyltransferase complex	MBT domain-containing protein 1	Homo sapiens (human)
nucleus	MBT domain-containing protein 1	Homo sapiens (human)
chromosome, telomeric region	TP53-binding protein 1	Homo sapiens (human)
site of double-strand break	TP53-binding protein 1	Homo sapiens (human)
kinetochore	TP53-binding protein 1	Homo sapiens (human)
nucleus	TP53-binding protein 1	Homo sapiens (human)
nucleoplasm	TP53-binding protein 1	Homo sapiens (human)
replication fork	TP53-binding protein 1	Homo sapiens (human)
cytoplasm	TP53-binding protein 1	Homo sapiens (human)
nuclear body	TP53-binding protein 1	Homo sapiens (human)
site of double-strand break	TP53-binding protein 1	Homo sapiens (human)
DNA repair complex	TP53-binding protein 1	Homo sapiens (human)
nucleus	TP53-binding protein 1	Homo sapiens (human)
nucleus	Lethal(3)malignant brain tumor-like protein 4	Homo sapiens (human)
nucleus	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
nucleoplasm	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
nucleolus	Lethal(3)malignant brain tumor-like protein 3	Homo sapiens (human)
spindle	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
nucleus	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
nucleoplasm	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
replication fork	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
nuclear matrix	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
chromatin	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
euchromatin	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
heterochromatin	E3 ubiquitin-protein ligase UHRF1	Homo sapiens (human)
nucleoplasm	PHD finger protein 23	Homo sapiens (human)
cytoplasm	PHD finger protein 23	Homo sapiens (human)
nucleus	PHD finger protein 23	Homo sapiens (human)
nucleus	Scm-like with four MBT domains protein 1	Homo sapiens (human)
nucleoplasm	Scm-like with four MBT domains protein 1	Homo sapiens (human)
nucleus	Scm-like with four MBT domains protein 1	Homo sapiens (human)
nucleolus	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
condensed chromosome	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
nucleus	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
nucleoplasm	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
chromatin lock complex	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
chromatin	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
nucleus	Lethal(3)malignant brain tumor-like protein 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID519968	Antiviral activity against HIV1 NL4-3 harboring M184L mutant RT infected in human MT2 cellssmeasured after 7 passages on day 34 postinfection	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID525238	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as nausea at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322841	Antiviral activity against Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/M204V/N236T mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID519876	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1693340	Antiviral activity against wild type HBV infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication at 10 uM measured after incubation of 72 hrs by RT-PCR analysis relative to control	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.
AID322839	Antiviral activity against lamivudine-adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1859028	Antiviral activity against HBV infected in human HepDES19 cells assessed as effect on levels of intracellular core protein 1 uM measured by Western blot assay	2022	Bioorganic & medicinal chemistry letters, 02-15, Volume: 58	4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID322831	Fold resistance, ratio of EC50 for adenofir-resistant HBV with reverse transcriptase N236T mutant to EC50 for wild-type HBV	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID283270	Inhibition of HBV replication with RT L228P substitution and M204I background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1694161	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry, 02-01, Volume: 31	Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents.
AID322845	Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase L180M/A181V mutant to wild-type HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1533172	Cytotoxicity against human HepG2.2.15 cells after 7 days by MTT assay	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Synthesis, Anti-HBV, and Anti-HIV Activities of 3'-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines.
AID1617348	Antiviral activity against HBV infected in BALB/c mouse hydrodynamic injection model hydrodynamically injected with replication-competent HBV DNA plasmid assessed as reduction in HBV DNA level in plasma at 0.1 mg/kg, po QD for 5 days by RT-qPCR analysis	2019	Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22	A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles.
AID519967	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells by phenosense assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1457761	Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy number after 6 days by real-time qPCR method	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1228485	Antiviral activity against Hepatitis B virus in HepG2.2.15 cells assessed as inhibition of intracellular viral DNA replication at 0.1 uM after 3 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID283259	Inhibition of HBV replication with RT A200V substitution and M204I background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID517932	Cytotoxicity against human HEK293 cells at 100 uM	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID519855	Antiviral activity against pseudotype HIV1 LAI-Luc infected in human PBMC measured on day 3 postinfection by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519873	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1678334	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNAs at 4 to 1000 nM incubated for 5 days by Southern blot analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID283263	Inhibition of HBV replication with RT I53F substitution and V173F, L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1599889	Antiviral activity against HBV genotype D hydrodynamically infected as pHBV1.3 mer plasmid carrying viral genome in C57BL/6 mouse assessed as reduction in serum viral DNA level at 0.1 to 1 mg/kg, po once daily and measured upto 6 days post treatment by qR	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID519857	Antiviral activity against pseudotype HIV1 NL-Luc infected in 24 hrs pretreated HEK293 cells by phenosense assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322849	Fold resistance, ratio of lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/M204V/N236T mutant to wild-type HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID525047	Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as mean viral clearance rate at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525226	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as gingival bleeding at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID519881	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1854350	Drug elimination in human urine assessed as unchanged drug administered po relative to control	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	HIV nucleoside reverse transcriptase inhibitors.
AID1422426	Antiviral activity against Hepatitis B virus infected in po dosed human liver chimeric uPA-SCID mouse assessed as reduction in serum HBeAg levels administered bid and measured for 21 days during compound dosing and follow-up period up to 35 days	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
AID322835	Antiviral activity against wild type HBV genotype E assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID517935	Antiviral activity against HIV1 subtype A isolate 1 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID519969	Antiviral activity against HIV infected in CD4+ lymphocyte by fluorescence-activated cell sorter assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID283264	Inhibition of HBV replication with RT S78T substitution from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID519867	Antiviral activity against HIV1 subtype B-ASM 034 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625938	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID519879	Antiviral activity against 0.006 MOI HIV1 NL4-3 infected in 1 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322825	Inhibition of wild type HBV replication in Huh7 cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID625935	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID519878	Antiviral activity against 0.006 MOI HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322832	Fold resistance, ratio of EC50 for lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant to EC50 for wild-type HBV	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID519851	Cytotoxicity against human CEM-SS cells after 10 days by MTT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID517936	Antiviral activity against HIV1 subtype A isolate 2 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID517937	Antiviral activity against HIV1 subtype B isolate 3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID283258	Inhibition of HBV replication with RT A200V substitution from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1457762	Cytotoxicity against human HepG2.2.15 cells assessed as cell viability by tetrazolium dye uptake assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID625939	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204I mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID519868	Antiviral activity against HIV1 subtype B-92US076 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519852	Cmax in human at 1 mg/kg, po	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID283275	Inhibition of HBV replication with RT M309L substitution from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID525234	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as thrombocytopenia at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322837	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/A181V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1678352	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 10000 nM incubated for 5 days by Southern blot analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID1694157	Antiviral activity against Hepatitis B virus infected in human HePAD38 cells assessed as reduction in viral DNA replication incubated for 7 days by RT-PCR analysis	2021	Bioorganic & medicinal chemistry, 02-01, Volume: 31	Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents.
AID525045	Hepatotoxicity in HBeAg-positive chronic hepatitis B patient assessed as reduction in alanine aminotransferase level at 0.5 mg/day after 12 weeks (Rvb = 170.2 IU/liter)	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1457764	Antiviral activity against HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy number after 6 days byr by real-time qPCR assay	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID322828	Antiviral activity against adenofir-resistant HBV with reverse transcriptase N236T mutant assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID525252	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as proteinuria at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID525242	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as headache at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1555316	Inhibition of capsid protein in lamivudine/entecavir-resistant Hepatitis B virus harboring rtL180M/rtM204V/rt184L mutant infected in human HepG2.2.15 cells assessed as reduction in viral DNA level at 10 uM measured after 72 hrs by PCR analysis relative to	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors.
AID525218	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as upper abdominal pain at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID519883	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322851	Fold resistance, ratio of entecavir-resistant HBV with reverse transcriptase L180M/S202G/M204V mutant to wild-type HBV genotype H	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1228493	Antiviral activity against Hepatitis B virus in HepG2.2.15 cells assessed as inhibition of intracellular viral DNA replication at 0.1 uM after 9 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID1649795	Cytotoxicity in human HepG2 cells assessed as induction of cell killing	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID1678339	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 40 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID525212	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as upper respiratory tract infection at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322827	Antiviral activity against wild type HBV assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID283262	Inhibition of HBV replication with RT V27A substitution and L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID519889	Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.005 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1377839	Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in cccDNA formation by measuring reduction in HBe antigen secretion at 10 uM after 14 days by ELISA relative to control	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.
AID1555318	Inhibition of capsid protein in wild type Hepatitis B virus infected in human HepG2.2.15 cells assessed as reduction of viral DNA level at 10 uM measured after 72 hrs by PCR analysis relative to control	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Assessment of quinazolinone derivatives as novel non-nucleoside hepatitis B virus inhibitors.
AID525220	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as increase in AST level at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID283268	Inhibition of HBV replication with RT C188S substitution and L80I, L180T, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID283271	Inhibition of HBV replication with RT L229W substitution and L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473613	Antiviral activity against HBV infected in hydrodynamic injection Balb/c mouse model assessed as log reduction in viral DNA load in liver at 0.1 mg/kg, po qd measured on day 8 post infection by RT-PCR method relative to control	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.
AID322847	Fold resistance, ratio of Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V mutant to wildtype HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1228497	Antiviral activity against Hepatitis B virus in HepG2.2.15 cells assessed as inhibition of extracellular viral DNA replication at 0.1 uM after 3 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID1377851	Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in extracellular viral DNA level by RT-PCR method	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.
AID1678338	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 13 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID1661467	Antiviral activity against HBV in AAV8-HBV-transduced Balb/c mouse assessed as reduction in HBV DNA level in plasma at 0.1 mg/kg, po QD for 4 weeks relative to control
AID525224	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as dyspnea at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID625941	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization me	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID519971	Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT to EC50 for 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID519854	Antiviral activity against pseudotype HIV1 LAI-Luc infected in human MT2 cells measured on day 3 postinfection by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1694158	Cytotoxicity against human PBMC cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry, 02-01, Volume: 31	Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents.
AID322833	Fold resistance, ratio of EC50 for lamivudine-adefovir-resistant HBV with reverse transcriptase L180M/M204V/N236T mutant to EC50 for wild-type HBV	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID322846	Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase V173L/L180/M204V mutant to wild-type HBV genotype H	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID625932	Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization method	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID517934	Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID525256	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as vomiting at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1228489	Antiviral activity against Hepatitis B virus in HepG2.2.15 cells assessed as inhibition of intracellular viral DNA replication at 0.1 uM after 6 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID283265	Inhibition of HBV replication with RT L80I substitution and L180M, M204I background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID625998	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hyb	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID525232	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as neutropenia at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1364073	Antiviral activity against entecavir-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1678347	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 40 nM incubated for 5 days by Southern blot analysis (R	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID1422422	Antiviral activity against Hepatitis B virus infected in human dHepaRG cells assessed as reduction in extracellular viral DNA levels after 6 days by qPCR/TaqMan assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
AID519856	Antiviral activity against pseudotype HIV1 NL-RLuc infected in human MT2 cells measured on day 5 postinfection by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID525042	Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as HBV DNA level in serum at 600 mg/day after 12 weeks (Rvb = 10.29 log10copies/ml)	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID283272	Inhibition of HBV replication with RT D263G substitution from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID519877	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519864	Antiviral activity against HIV1 subtype B-NL4-3 infected in 2 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1742101	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 10 uM supplemented with fresh medium containing compound every 2 days for 6 days by RT-PCR analysis relative to control	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
AID1661461	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in capsid associated DNAs at 0.1 uM by agarose gel electrophoresis method
AID519875	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1617347	Antiviral activity against HBV infected in BALB/c mouse hydrodynamic injection model hydrodynamically injected with replication-competent HBV DNA plasmid assessed as reduction in HBV DNA level in liver at 0.1 mg/kg, po QD for 5 days by RT-qPCR analysis	2019	Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22	A New Approach of Mitigating CYP3A4 Induction Led to the Discovery of Potent Hepatitis B Virus (HBV) Capsid Inhibitor with Optimal ADMET Profiles.
AID283269	Inhibition of HBV replication with RT V224A substitution and V173L, L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID369218	Antiviral activity against woodchuck hepatitis virus infected woodchucks assessed as log reduction of serum viral DNA per ml of serum after 4 weeks	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	Antiviral effect of orally administered (-)-beta-D-2-aminopurine dioxolane in woodchucks with chronic woodchuck hepatitis virus infection.
AID519869	Antiviral activity against HIV1 subtype B-ASM 044 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519871	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID283266	Inhibition of HBV replication with RT K168E substitution and M204I background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1678350	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 1100 nM incubated for 5 days by Southern blot analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID517941	Antiviral activity against HIV1 subtype C isolate 7 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID519888	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1351361	Antiviral activity against lamivudine/entecavir resistant HBV harboring reverse transcriptase L180M/M204V/T184L mutant infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 10 uM after 72 hrs by RT-PCR method relative to	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID283260	Inhibition of HBV replication with RT A200V substitution and L180M, M204I background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1694159	Cytotoxicity against human CEM cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry, 02-01, Volume: 31	Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents.
AID519859	Antiviral activity against HIV1 subtype B-RF infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID727269	Cytotoxicity against human HuH7 cells	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
AID525236	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as increase in blood CK level at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID523463	Antiviral activity against Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as decrease in intracellular viral DNA level at 2.16 uM after 72 hrs by RT-PCR analysis	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Heat stress cognate 70 host protein as a potential drug target against drug resistance in hepatitis B virus.
AID1649793	Antiviral activity against multidrug-resistant HBV infected in human HepG2.1403F cells assessed as reduction in viral replication incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID1533171	Antiviral activity against HBV genotype D infected in human HepG2.2.15 cells assessed as reduction in viral DNA level after 7 days by RT-PCR assay	2018	ACS medicinal chemistry letters, Dec-13, Volume: 9, Issue:12	Synthesis, Anti-HBV, and Anti-HIV Activities of 3'-Halogenated Bis(hydroxymethyl)-cyclopentenyladenines.
AID1351359	Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral DNA replication at 10 uM after 72 hrs by RT-PCR method relative to control	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors.
AID525246	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as insomnia at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322843	Antiviral activity against entecavir-resistant HBV with reverse transcriptase L180M/S202G/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1631968	Antiviral activity against Hepatitis B virus genotype D infected in Balb/c mouse assessed as reduction in viral DNA level in liver at 0.1 mg/kg, po qd for 5 days by RT-PCR method	2016	Journal of medicinal chemistry, 08-25, Volume: 59, Issue:16	Design and Synthesis of Orally Bioavailable 4-Methyl Heteroaryldihydropyrimidine Based Hepatitis B Virus (HBV) Capsid Inhibitors.
AID1364074	Antiviral activity against entecavir-resistant wild type hepatitis B virus infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID519966	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells by phenosense assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519853	Antiviral activity against pseudotype HIV1 LAI-Luc infected in CD4-positive human HeLa cells measured on day 3 postinfection by luciferase reporter gene assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519887	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322840	Antiviral activity against Lamivudine -adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1377854	Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in intracellular viral DNA level at 10 uM by RT-PCR method relative to control	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.
AID626001	Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot hybridization meth	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID727270	Antiviral activity against wild type Hepatitis B virus infected in human HuH7 cells	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
AID322842	Antiviral activity against lamivudine-adenofir-resistant HBV with reverse transcriptase V173L/L180M/A181V/N236T mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID519874	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1678340	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 120 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID1859031	Antiviral activity against HBV infected in human HepDES19 cells assessed as reduction of capsid associated HBV DNA 1 uM measured by agarose gel electrophoresis-based particle gel assay	2022	Bioorganic & medicinal chemistry letters, 02-15, Volume: 58	4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID525254	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as vaginal hemorrhage at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322826	Effect on cell viability in human Huh7 cells	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1695272	Cytotoxicity against human HepG2.2.15.7 cells assessed as reduction in cell viability	2020	RSC medicinal chemistry, May-01, Volume: 11, Issue:5	Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin.
AID519860	Antiviral activity against HIV1 subtype B-SF-2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1678337	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 4 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1678342	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 1100 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID322838	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase V173L/L180/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1228505	Antiviral activity against Hepatitis B virus in HepG2.2.15 cells assessed as inhibition of extracellular viral DNA replication at 0.1 uM after 9 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID1678358	Toxicity in HBV infected hydrodynamic injection C57BL/6 mouse model assessed as effect on body weight at 0.6 to 60 mg/kg, po QD for 6 days	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID517943	Antiviral activity against HIV1 expressing reverse transcriptase D67N/K70R/T215F/K219E/M184V mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID1678345	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 4 nM incubated for 5 days by Southern blot analysis (Rv	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID525222	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as conjunctival hypermia at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID519862	Antiviral activity against HIV1 subtype B-LAI infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID283273	Inhibition of HBV replication with RT Q267Stop substitution and L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1228501	Antiviral activity against Hepatitis B virus in HepG2.2.15 cells assessed as inhibition of extracellular viral DNA replication at 0.1 uM after 6 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID519870	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID525049	Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as mean rate of infected cell loss at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1363957	Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID517939	Antiviral activity against HIV1 subtype BF isolate 5 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID1678348	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 120 nM incubated for 5 days by Southern blot analysis (	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID1678335	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNAs up to 100 uM incubated for 5 days by Southern blot analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID727268	Antiviral activity against entecavir-resistant Hepatitis B virus harboring L180M/M204V/S202G triple mutant infected in human HuH7 cells	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID519884	Antiviral activity against 0.05 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1363962	Cytotoxicity in human HepG2.215 cells assessed as reduction in cell viability after 5 days by CCK8 assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID525230	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as myalgia at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1695271	Antiviral activity against Hepatitis B virus infected in human HepG2.2.15.7 assessed as reduction in HBV DNA level incubated for 9 days media replaced every 3 days once with test compound by RT-PCR analysis	2020	RSC medicinal chemistry, May-01, Volume: 11, Issue:5	Synthesis and anti-HBV activity of carbocyclic nucleoside hybrids with salient features of entecavir and aristeromycin.
AID519863	Antiviral activity against HIV1 subtype B-NL4-3 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1228457	Cytotoxicity against human HepG2.2.15 cells by MTT assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID626004	Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as inhibition of virus replication treated daily for 9 days by quantitative blot h	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID525250	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as nasophayngitis at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID525240	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as facial edema at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322829	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID519861	Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID525214	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as chest discomfort at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1649792	Antiviral activity against HBV infected in human HepG2.A64 cells containing reverse transcriptase L180M/T184L/M204V mutant assessed as reduction in viral replication incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID1473614	Antiviral activity against HBV infected in hydrodynamic injection Balb/c mouse model assessed as log reduction in viral DNA load in plasma at 0.1 mg/kg, po qd measured up to day 8 post infection by RT-PCR method relative to control	2018	Journal of medicinal chemistry, 02-08, Volume: 61, Issue:3	3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4.
AID1457763	Selectivity index, ratio of CC50 for HepG2.2.15 cells to EC50 for HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring extracellular viral DNA copy	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID525216	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as abdominal discomfort at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID727267	Selectivity ratio of EC50 for entecavir-resistant Hepatitis B virus harboring L180M/M204V/S202G triple mutant to EC50 for wild type Hepatitis B virus	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
AID1377853	Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in intracellular viral DNA level by RT-PCR method	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.
AID525053	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as increase in ALT level at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1678344	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 10000 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID625996	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1661464	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in capsid formation
AID519858	Antiviral activity against HIV1 subtype B-HXB2 infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1678343	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 3300 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID322830	Antiviral activity against lamivudine-adefovir-resistant HBV with reverse transcriptase L180M/M204V/N236T mutant assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID525051	Antiviral activity against Hepatitis B virus in HBeAg-positive chronic hepatitis B patient assessed as mean efficiency factor of blocking virus production at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1678351	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 3300 nM incubated for 5 days by Southern blot analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID519849	Antiviral activity against Hepatitis B virus	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1693342	Antiviral activity against lamivudine/entecavir-resistant HBV rtL180M/rtM204V/rtT184L mutant infected in human HepG2 2.2.15 cells assessed as inhibition of viral DNA replication at 10 uM measured after incubation of 72 hrs by RT-PCR analysis relative to c	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Synthesis and evaluation of new phenyl acrylamide derivatives as potent non-nucleoside anti-HBV agents.
AID1678357	Antiviral activity against HBV infected hydrodynamic injection C57BL/6 mouse model assessed as reduction in serum HBV DNA level at 0.6 to 60 mg/kg, po QD for 6 days by qPCR analysis	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID283274	Inhibition of HBV replication with RT G295S substitution and L80I, M204I background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1678349	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 370 nM incubated for 5 days by Southern blot analysis (	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID519880	Antiviral activity against 0.006 MOI HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1859022	Antiviral activity against HBV infected in human HepDES19 cells assessed effect on intracellular total HBV RNA at 1 uM measured after 24 hrs by northern blot hybridization assay	2022	Bioorganic & medicinal chemistry letters, 02-15, Volume: 58	4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID1854349	Elimination half life in human administered po	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	HIV nucleoside reverse transcriptase inhibitors.
AID1678346	Antiviral activity against adenovirus AdH294-WT harboring wild-type HBV genotype D accession #V01460 infected in human HepG2 cells assessed as reduction in viral replicative intermediate DNA level at 13 nM incubated for 5 days by Southern blot analysis (R	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID322834	Antiviral activity against wild type HBV genotype H assessed as inhibition of replication	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID525260	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as muscular weakness at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1859025	Antiviral activity against HBV infected in human HepDES19 cells assessed reduction of amounts of encapsidated pgRNA 1 uM measured after 24 hrs by northern blot hybridization assay	2022	Bioorganic & medicinal chemistry letters, 02-15, Volume: 58	4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID519970	Cmax in human blood	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID519882	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1363984	Antiviral activity against entecavir-resistant hepatitis B virus harboring reverse transcriptase M204I/S202G/M250V triple mutant infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1678341	Antiviral activity against ETV-resistant and adenovirus AdH294-7LR harboring wild-type HBV infected in human HepG2 cells assessed as viral replicative intermediate DNA level at 370 nM incubated for 5 days by Southern blot analysis (Rvb = 100%)	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.
AID519964	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID625936	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase M204V mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hyb	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID626005	Antiviral activity against lamivudine/entecavir-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V/S202G infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative So	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID519865	Antiviral activity against HIV1 subtype B-NL4-3 infected in 3 hrs pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519972	Selectivity ratio of EC50 for 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT to EC50 for 0.005 MOI HIV1 NL4-3 harboring wild type RT infected in human MT2 cells by phenosense assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1422421	Antiviral activity against Hepatitis B virus infected in human dHepaRG cells assessed as reduction in HBeAg secretion after 10 mins by chemiluminescence immunoassay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
AID519890	Selectivity ratio of EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by MTS assay to EC50 for 0.01 MOI HIV1 NL4-3 infected in human MT2 cells by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID525248	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as myringitis at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID519886	Antiviral activity against 0.01 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1854347	Antiviral activity against HIV-1	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	HIV nucleoside reverse transcriptase inhibitors.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID519973	Antiviral activity against HIV1 NL4-3 harboring M184V mutant RT at 2.5 uM after 6 days	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322848	Fold resistance, ratio of Lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/M204V mutant to wildtype HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID626002	Antiviral activity against adefovir-resistant Hepatitis B virus harboring reverse transcriptase N236T mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hybri	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1363983	Antiviral activity against entecavir-resistant hepatitis B virus harboring reverse transcriptase M204I/S202G double mutant infected in human Huh7 cells assessed as reduction in intracellular DNA levels measured on day 7 by real-time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID517938	Antiviral activity against HIV1 subtype B isolate 4 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID322836	Antiviral activity against lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID525244	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as hordeolum at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID322844	Fold resistance, ratio of lamivudine-resistant HBV with reverse transcriptase L180M/M204V mutant to wild-type HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID1228456	Antiviral activity against Hepatitis B virus in HepG2.CW cells assessed as inhibition of viral DNA replication at 1 uM after 9 days by real-time FQ-PCR analysis	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	Synthesis and biological evaluation of 4-substituted fluoronucleoside analogs for the treatment of hepatitis B virus infection.
AID519866	Antiviral activity against HIV1 subtype B-93US143 infected in 1 hr-pretreated PBMC cells assessed as inhibition of p24 antigen production measured on day 5 postinfection by ELISA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1457789	Selectivity index, ratio of CC50 for HepG2.2.15 cells to EC50 for HBV ayw1 infected in human HepG2(2.2.15) cells assessed as reduction in viral replication by measuring intracellular viral DNA copy	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.
AID1859030	Antiviral activity against HBV infected in human HepDES19 cells assessed as effect on levels of intracellular core capsid 1 uM measured by Western blot assay	2022	Bioorganic & medicinal chemistry letters, 02-15, Volume: 58	4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators.
AID283267	Inhibition of HBV replication with RT A181T substitution and V173L, L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID1422428	Antiviral activity against Hepatitis B virus infected in po dosed human liver chimeric uPA-SCID mouse assessed as log reduction in serum viral DNA levels administered bid and measured for 21 days during compound dosing and follow-up period up to 35 days	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
AID1363985	Antiviral activity against entecavir-resistant hepatitis B virus harboring reverse transcriptase M204I/S202G double mutant infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1742103	Antiviral activity against lamivudine and entecavir-resistant HBV harboring rtL180 M/rtM204V/rtT184L mutant infected in human HepG2.2.15 cells assessed as inhibition of DNA replication at 10 uM supplemented with fresh medium containing compound every 2 da	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	Discovery of novel quinazolinone derivatives as potential anti-HBV and anti-HCC agents.
AID1363986	Antiviral activity against entecavir-resistant hepatitis B virus harboring reverse transcriptase M204I/S202G/M250V triple mutant infected in human Huh7 cells assessed as reduction in secreted DNA levels measured on day 7 by real-time PCR analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4).
AID1599886	Toxicity against C57BL/6 mouse hydrodynamically infected with pHBV1.3 mer plasmid carrying HBV genotype D assessed as change in body weight at 0.1 to 1 mg/kg, po once daily and measured upto 6 days post treatment	2019	ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6	Design, Synthesis, and Anti-HBV Activity of New Bis(l-amino acid) Ester Tenofovir Prodrugs.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1649794	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID525258	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as peripheral neuropathy at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID517942	Antiviral activity against HIV1 subtype D isolate 8 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID517940	Antiviral activity against HIV1 subtype C isolate 6 infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID517944	Antiviral activity against HIV1 expressing reverse transcriptase K103N/Y181C/G190A mutant infected in HEK293 cells assessed as inhibition of virus replication after 72 hrs	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625934	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1377846	Inhibition of capsid in HBV infected in human HepAD38 cells assessed as reduction in tetracycline-induced cccDNA formation by measuring reduction in HBe antigen secretion after 14 days by ELISA	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of sulfamoylbenzamide derivatives as HBV capsid assembly effector.
AID1422425	Antiviral activity against Hepatitis B virus infected in po dosed human liver chimeric uPA-SCID mouse assessed as reduction in serum HBsAg levels administered bid and measured for 21 days during compound dosing and follow-up period up to 35 days	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
AID1422420	Antiviral activity against Hepatitis B virus infected in human dHepaRG cells assessed as reduction in HBsAg secretion after 10 mins by chemiluminescence immunoassay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action.
AID625999	Antiviral activity against lamivudine-resistant Hepatitis B virus harboring reverse transcriptase L180M/M204V double mutant infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Sout	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID625933	Antiviral activity against wild type Hepatitis B virus infected in human HepG2(2.2.15) cells assessed as reduction of infectious virus titer treated daily for 9 days by quantitative Southern blot hybridization assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Antiviral activity of novel 2'-fluoro-6'-methylene-carbocyclic adenosine against wild-type and drug-resistant hepatitis B virus mutants.
AID1659438	Antiviral activity against Hepatitis B virus infected in C57BL/6 mouse assessed as reduction in viral DNA at 0.1 mg/kg, po measured upto 6 days by qRT-PCR analysis
AID519885	Antiviral activity against 0.005 MOI wild type HIV1 NL4-3 infected in 2 hr-pretreated human MT2 cells measured after 5 days by MTS assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1694160	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	2021	Bioorganic & medicinal chemistry, 02-01, Volume: 31	Discovery and structure activity relationship of glyoxamide derivatives as anti-hepatitis B virus agents.
AID1649770	Antiviral activity against HBV infected in human HepAD38 cells assessed as reduction in viral DNA levels incubated for 6 days by PCR analysis	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	Discovery of (1
AID519963	Antiviral activity against HIV1 3B infected in MOLT-4/3B cells assessed as inhibition of mature virus release measured after 4 days of infection by RT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID1350670	Antiviral activity against HBV genotype D infected in chimeric mouse with humanized liver assessed as log reduction in viral DNA level in serum at 0.03 mg/kg, po qd for 28 days by RT-PCR method	2018	Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14	Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).
AID283261	Inhibition of HBV replication with RT L80V substitution and L180M, M204V background from Lamivudine refractory patient transfected into HepG2 cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
AID519872	Antiviral activity against 0.02 MOI wild type HIV1 NL4-3 infected in human MT2 cells measured after 5 days by RT SPA	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519965	Antiviral activity against 0.005 MOI HIV1 NL4-3 harboring M184V mutant RT infected in human MT2 cells	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID519850	Antiviral activity against HIV1 infected in human CEM-SS cells after 10 days by MTT assay	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
AID322850	Fold resistance, ratio of Lamivudine -adenofir-resistant with HBV reverse transcriptase V173L/L180M/A181V/N236T mutant to wildtype HBV genotype E	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.
AID525228	Toxicity in HBeAg-positive chronic hepatitis B patient assessed as hyperphosphatemia at 0.5 mg/day	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B.
AID1854348	Oral bioavailability in human relative to control	2022	European journal of medicinal chemistry, Oct-05, Volume: 240	HIV nucleoside reverse transcriptase inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID771610	Selectivity ratio of IC50 for L3MBTL1 (unknown origin) to IC50 for L3MBTL3 (unknown origin) by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771603	Displacement of mero76 from GFP-L3MBTL3 (unknown origin) expressed in HEK293 cells at 5 uM after 3 hrs by immunofluorescence assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771608	Binding affinity to L3MBTL1 (unknown origin) by isothermal titration calorimetric assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771612	Inhibition of PHF23 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771611	Inhibition of JARID1A (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771615	Inhibition of MBTD1 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771619	Inhibition of L3MBTL1 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771607	Selectivity ratio of Kd for L3MBTL1 (unknown origin) to Kd for L3MBTL3 (unknown origin) by isothermal titration calorimetric assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID1077873	Inhibition of CBX7 (8 to 62) (unknown origin) expressed in Escherichia coli BL21 Rosetta DE3 using H3K9Me3 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID1578927	Inhibition of L3MBTL3 (unknown origin) assessed as dissociation constant by isothermal titration calorimetry	2019	Journal of medicinal chemistry, 10-24, Volume: 62, Issue:20	Discovery of a Potent and Selective Fragment-like Inhibitor of Methyllysine Reader Protein Spindlin 1 (SPIN1).
AID1077870	Inhibition of GST-tagged PHF23 (unknown origin) using H3K4Me3 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID771623	Cytotoxicity against HEK293T/17 cells assessed as cell viability up to 100 uM after 24 hrs by CellTiter-Glo luminescence assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771604	Displacement of mero76-UNC1215 from GFP-L3MBTL3 (unknown origin) expressed in HEK293 cells at 1 equivalent dose after 3 hrs by immunofluorescence assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771618	Inhibition of L3MBTL4 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771606	Antagonist activity at muscarinic M1 receptor (unknown origin) expressed in HEK293T cells assessed as inhibition of UNC1679 calcium mobilization	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID1077875	Inhibition of MBTD1 (130 to 566) (unknown origin) expressed in Escherichia coli BL21 Rosetta DE3 using H4K20Me1 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID771617	Inhibition of SFMBT1 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID1077872	Inhibition of UHRF1 tandem tudor domain (121 to 286) (unknown origin) expressed in Escherichia coli BL21 Rosetta DE3 using H3K9Me3 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScree	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID1077876	Inhibition of His-tagged L3MBTL1 (unknown origin) using H4K20Me1 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID1077874	Inhibition of 53BP1 (1485 to 1611) (unknown origin) expressed in Escherichia coli BL21 Rosetta DE3 using H4K20Me2 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID771602	Binding affinity to L3MBTL3 in human G401 cells by Western blot based pulldown assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771614	Inhibition of UHRF1 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771621	Inhibition of L3MBTL3 (unknown origin) using H4K20me2 as substrate after 30 mins by LNCE-TR-FRET assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771620	Inhibition of L3MBTL3 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID1077877	Inhibition of His-tagged L3MBTL3 (unknown origin) using H4K20Me2 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID771616	Inhibition of CBX7 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771609	Binding affinity to L3MBTL3 (unknown origin) by isothermal titration calorimetric assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID1077871	Inhibition of GST-tagged Jarid1A (unknown origin) using H3K4Me3 as substrate incubated for 30 mins at room temperature followed by incubation under dark condition for 30 mins by AlphaScreen assay	2013	MedChemComm, Nov, Volume: 4, Issue:11	The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface.
AID771601	Ratio of Kd for L3MBTL1 L361F mutant (unknown origin) to Kd for wild type L3MBTL1 (unknown origin) by isothermal titration calorimetric assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID771613	Inhibition of 53BP1 (unknown origin) after 30 mins by AlphaScreen assay	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Small-molecule ligands of methyl-lysine binding proteins: optimization of selectivity for L3MBTL3.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346246	Human L3MBTL3, histone methyl-lysine binding protein (Methyllysine reader proteins)	2013	Nature chemical biology, Mar, Volume: 9, Issue:3	Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (0.28)	18.2507
2000's	257 (14.38)	29.6817
2010's	1169 (65.42)	24.3611
2020's	356 (19.92)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	248 (13.33%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	276 (14.84%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	177 (9.52%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	43 (2.31%)	0.25%
Observational	0 (0.00%)	0.25%
Other	1,116 (60.00%)	84.16%
Other	17 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (237)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
An, Open-label, Multicenter, Randomized, Active Control Study, Comparing P1101 Monotherapy to Entecavir Monotherapy in Patients With HBeAg-negative Chronic Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy [NCT05494528]		90 participants (Anticipated)	Interventional	2021-05-04	Recruiting
Study of the Antiviral Activity of Entecavir in Patients Receiving Liver Transplant Due to Chronic Hepatitis B Virus Infection [NCT00395018]	Phase 3	109 participants (Actual)	Interventional	2007-04-30	Completed
The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial [NCT03509688]		312 participants (Actual)	Interventional	2014-11-30	Completed
Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study [NCT02505009]	Phase 4	116 participants (Actual)	Interventional	2015-05-01	Completed
Study on Three Types of Nucleotide/Nucleoside Analogues Treatment in Patients With Hepatitis b Virus Related Acute-on-chronic Liver Failure [NCT03920618]		150 participants (Anticipated)	Interventional	2019-02-01	Recruiting
Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial [NCT01148576]	Phase 4	1,200 participants (Anticipated)	Interventional	2010-06-30	Recruiting
Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B [NCT02532413]	Phase 4	180 participants (Anticipated)	Interventional	2015-07-31	Recruiting
Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection [NCT01341106]	Phase 4	7 participants (Actual)	Interventional	2011-04-30	Terminated(stopped due to insufficient patient numbers have been recruited)
A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and a PD-1 Inhibitor in Chronic Hepatitis B Patients [NCT05275023]	Phase 2	37 participants (Actual)	Interventional	2022-06-30	Active, not recruiting
A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ [NCT04585789]	Phase 2	24 participants (Actual)	Interventional	2021-03-11	Active, not recruiting
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hep [NCT04535544]	Phase 2	52 participants (Actual)	Interventional	2020-09-17	Active, not recruiting
A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection [NCT04398134]	Phase 2	88 participants (Actual)	Interventional	2020-08-28	Terminated(stopped due to Study stopped due to a safety signal of drug-induced liver injury in subjects receiving 2158)
A Phase IIa Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With Entecavir (ETV) Compared With ETV Monotherapy in Patients With Chronic Hepatitis B Who Have Received ETV Monotherapy for at Least 12 Months [NCT05484466]	Phase 2	90 participants (Anticipated)	Interventional	2022-11-11	Recruiting
Pilot Study of First Line Combination Treatment With Low Dose Pegylated Interferon and Entecavir in Treatment-naïve Patients With Chronic Hepatitis B. [NCT01589952]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2012-03-31	Recruiting
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human Study of Orally Administered ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single-Ascending Doses (Part 1) and Multiple-Ascending Doses in H [NCT04536337]	Phase 1	336 participants (Anticipated)	Interventional	2020-10-22	Recruiting
A Phase IV, 2x2 Factorial, Double Blind Study of 48 Versus 96 Weeks of PEGASYS 180µg, With or Without 24 Weeks of Entecavir in Adult Patients With HBeAg Negative Chronic Hepatitis B. [NCT01179594]	Phase 4	0 participants (Actual)	Interventional	2010-09-18	Withdrawn(stopped due to This study was canceled for operational reasons.)
A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 as Adjunctive Therapy in Virally-suppressed Patients With Chronic Hepatitis B [NCT03576066]	Phase 2	73 participants (Actual)	Interventional	2018-06-11	Completed
A Study of the Safety and Efficacy of Entecavir Plus Tenofovir in Adults With Chronic Hepatitis B Virus Infection With Previous Nucleoside/Nucleotide Treatment Failure [NCT01063036]	Phase 3	144 participants (Actual)	Interventional	2010-05-31	Completed
Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment [NCT02365402]	Phase 4	180 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a [NCT02368288]	Phase 4	200 participants (Anticipated)	Interventional	2013-01-31	Recruiting
A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) [NCT02327416]	Phase 3	300 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Continuation of Lamivudine Plus Adefovir Versus Switching to Entecavir Plus Adefovir in Adults With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir [NCT01023217]	Phase 4	90 participants (Actual)	Interventional	2009-11-30	Completed
A Open-label, Single Center Drug Interaction Study of Morphothiadine Mesilate/Ritonavir , Entecavir and Tenofovir Disoproxil Fumarate in Healthy Subjects [NCT03662568]	Phase 1	56 participants (Actual)	Interventional	2018-06-26	Completed
A Sequential Phase 1a/1b Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ARC-521 in Normal Adult Volunteers and Patients With Chronic Hepatitis B [NCT02797522]	Phase 1	47 participants (Actual)	Interventional	2016-06-30	Terminated(stopped due to Company decision to discontinue trial)
Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir [NCT02097004]	Phase 4	111 participants (Actual)	Interventional	2014-04-30	Completed
A Multi-center, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Generic Entecavir Monotherapy or in Combination With Adefovir for Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy [NCT01341743]	Phase 4	360 participants (Anticipated)	Interventional	2010-12-31	Active, not recruiting
Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B [NCT02075294]		242 participants (Actual)	Observational	2010-01-31	Completed
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of Oral FXR Modulator EYP001a Combined With Nucleos(t)Ide Analogues (NA) in Virologically Suppressed Chronic Hepatitis B Patients to Improve Functional Cure Rates [NCT04465916]	Phase 2	26 participants (Actual)	Interventional	2020-05-12	Terminated(stopped due to DSMC reviewed results of 26 subjects. New randomizations were stopped. Already randomized subjects were followed up to W40.)
A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers [NCT03568578]		450 participants (Anticipated)	Interventional	2018-01-28	Recruiting
A Prospective Open Label Control Study to Evaluate the Efficacy and Safety of Entecavir Treatment of Patients With Acute on Chronic Hepatitis B Liver Failure [NCT01254994]	Phase 2	108 participants (Actual)	Interventional	2007-08-31	Completed
A Single-Center, Open-Label, Randomized, Single-Dose, Two-Period, Two-Sequence, Crossover Study to Assess the Bioequivalence of Entecavir Tablets 1.0 mg With Baraclude® 1.0 mg in Healthy Adult Subjects Under Fasting Conditions [NCT03847246]		26 participants (Actual)	Interventional	2018-12-04	Completed
A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection [NCT03253250]	Phase 4	432 participants (Anticipated)	Interventional	2017-09-01	Recruiting
Metformin as Add-on to the Standard Therapy in Patients With Chronic Hepatitis B: A Randomized, Double-Blind, Placebo-Controlled Trial [NCT04182321]		60 participants (Actual)	Interventional	2020-03-13	Completed
Randomized, Open-Label, Comparative Study to Evaluate Early Viral Load Reductions and Exploratory Viral Kinetics Following Administration of Entecavir or Adefovir in Nucleoside-Naive Adults With Chronic Hepatitis B Infection [NCT00096785]	Phase 3	69 participants (Actual)	Interventional	2004-12-31	Completed
Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors in Chinese Patients of Hepatitis B [NCT03680183]		300 participants (Anticipated)	Observational [Patient Registry]	2018-05-22	Recruiting
A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection [NCT04294498]	Phase 2	43 participants (Anticipated)	Interventional	2020-11-02	Recruiting
A Phase II Study of the Safety and Efficacy of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients Who Have Hepatitis B Viremia While Being Treated With Lamivudine [NCT00051038]	Phase 2/Phase 3	0 participants	Interventional	2002-09-30	Completed
[NCT00036608]	Phase 3	0 participants	Interventional	2002-01-31	Completed
A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects With Chronic Hepatitis B Virus Infection [NCT04820686]	Phase 2	65 participants (Actual)	Interventional	2021-05-07	Terminated(stopped due to Sponsor decision)
A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B [NCT03109730]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2017-06-15	Completed
A Study to Describe the Antiviral Effect of Entecavir (ETV) in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection Who Are Nucleoside-Naive [NCT00371150]	Phase 4	131 participants (Actual)	Interventional	2006-11-30	Completed
A Phase II Study in Japan of the Safety And Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B With Incomplete Response to Current Lamivudine Therapy [NCT01037166]	Phase 2	84 participants (Actual)	Interventional	2002-12-31	Completed
Investigator Initiated Study of Thymosin in HBV-related HCC [NCT02281266]	Phase 4	360 participants (Anticipated)	Interventional	2015-01-31	Not yet recruiting
Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B [NCT02288208]	Phase 1	7 participants (Actual)	Interventional	2014-11-30	Terminated(stopped due to Due to cranial nerve palsies observed)
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study of FG-3019 in Subjects With Liver Fibrosis Due to Chronic Hepatitis B Infection [NCT01217632]	Phase 2	114 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Study terminated due to an unexpected prominent effect of entecavir alone in this patient population.)
A Randomized, Multi Center, Phase IIIb Open-label Study to Evaluate the Efficacy of Sequential Therapy of Peginterferon Alfa-2a(Pegasys(TM)) Following Entercavir Compared With Peginterferon Alfa-2a Monotherapy in Patient With HBeAg Positive Chronic Hepati [NCT01220596]	Phase 3	228 participants (Anticipated)	Interventional	2010-06-30	Recruiting
The Beneficial Effect of Vitamin D Supplement to Peg Interferon Alpha 2a or to Telbivudine Monotherapy in Patients With Chronic HBV Viral Infection [NCT01083251]		120 participants (Anticipated)	Interventional	2010-03-31	Recruiting
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study) [NCT02849132]	Phase 4	800 participants (Anticipated)	Interventional	2016-01-31	Active, not recruiting
Comparison of the Efficacy and Safety of Entecavir Versus Adefovir in Subjects Chronically Infected With Hepatitis B Virus and Evidence of Hepatic Decompensation [NCT00065507]	Phase 3	195 participants (Actual)	Interventional	2003-08-31	Completed
Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients With Chronic Hepatitis B Virus Infection Who Are HBeAg-positive [NCT01204762]	Phase 2	197 participants (Actual)	Interventional	2010-11-30	Completed
An Open-Label Rollover Study of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Previous Phase II Studies in Japan But Who Require Further Treatment [NCT01037062]	Phase 2	282 participants (Actual)	Interventional	2003-12-31	Completed
[NCT01139203]		300 participants (Anticipated)	Interventional	2009-08-31	Recruiting
Induction of HBsAg Decline Using an add-on Treatment of Peginterferon Alfa-2a in HBeAg-negative Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogous (PAS) [NCT01373684]	Phase 4	90 participants (Actual)	Interventional	2012-05-25	Completed
A Multinational, Multi-center, Open, Comparative, Paralleled, Roll-over Study to Assess the Safety and Antiviral Activity of LB80380 Tablet Compared to Entecavir 0.5 mg After Additional 48 Weeks of Treatment in Chronic Hepatitis B Patients Who Have Comple [NCT01242787]	Phase 2	115 participants (Anticipated)	Interventional	2010-08-31	Active, not recruiting
A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis B Virus (HBV) Infection [NCT02738008]	Phase 2	12 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to Company decision to discontinue trial)
A Multicenter, Randomized, Open-label Control Study to Evaluate Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients [NCT03448744]	Phase 4	240 participants (Anticipated)	Interventional	2017-10-25	Recruiting
A Study to Compare and Evaluate Intrahepatic cccDNA Reduction After Administrating Clevudine or Entecavir in the Chronic HBV Patients [NCT01266005]	Phase 4	75 participants (Anticipated)	Interventional	2009-08-31	Terminated
The Effect of Entecavir Consolidation on Post-TDF Treatment Durability [NCT03308890]	Phase 4	156 participants (Anticipated)	Interventional	2017-11-01	Not yet recruiting
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) Versus Placebo in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive [NCT01079806]	Phase 3	180 participants (Actual)	Interventional	2010-06-30	Completed
Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA [NCT00637663]	Phase 4	72 participants (Actual)	Interventional	2008-02-29	Completed
A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an Equivalent Dose of a Reference Drug Product (Baraclude 0.5mg Tablets) in Healthy Adult [NCT02850848]	Phase 4	39 participants (Actual)	Interventional	2015-12-31	Completed
Efficacy of Switch or Sequential Combination Therapy of Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Low HBsAg and HBeAg Titers After Long-term Entecavir Therapy: A Multicenter, Prospective Cohort Study [NCT02589652]		294 participants (Anticipated)	Observational	2015-10-31	Not yet recruiting
Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma [NCT00768157]	Phase 4	200 participants (Anticipated)	Interventional	2007-04-30	Recruiting
A Randomized, Controlled Study to Evaluate the Efficacy and Significant of the Anti-virus Therapy for the Unresectable Hepatitis B Virus-related Primary Liver Cancer [NCT00824707]		200 participants (Actual)	Interventional	2008-12-31	Completed
A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection [NCT01020565]	Phase 2	60 participants (Anticipated)	Interventional	2003-02-28	Completed
A Study of the Safety and Antiviral Activity of Open-Label Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection Who Have Completed Dosing in a Previous Phase II/III Study in China [NCT00975091]	Phase 3	600 participants (Actual)	Interventional	2004-05-31	Completed
Combination Entecavir and Peginterferon Therapy in HBeAg-Positive Immune-Tolerant Adults With Chronic Hepatitis B [NCT01369199]	Phase 3	28 participants (Actual)	Interventional	2012-05-31	Terminated
A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, [NCT02604212]	Phase 2	32 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to Company decision to discontinue trial)
Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN) [NCT01368497]	Phase 3	60 participants (Actual)	Interventional	2012-09-30	Completed
A Single and Repeated Dose Escalation, Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics and Preliminary Pharmacodynamics of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection [NCT05017116]	Phase 1	40 participants (Actual)	Interventional	2021-08-09	Completed
A Phase IIb, Open, Multinational, Multi-center, Randomised, Comparative, Parallel Study to Assess the Safety and Antiviral Activity of LB80380 Compared to Entecavir 0.5 mg in Chronic Hepatitis B Patients for 48 Weeks With a Planned Analysis of Efficacy an [NCT01026610]	Phase 2	115 participants (Actual)	Interventional	2009-08-31	Completed
A Clinical Study to Evaluate the Steady State Pharmacokinetics of Baraclude in Participants With Hepatitis B Virus Infection [NCT03083821]	Phase 1	6 participants (Actual)	Interventional	2017-05-16	Completed
A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients [NCT01588912]	Phase 4	104 participants (Anticipated)	Interventional	2012-04-30	Recruiting
A Comparative Study of Entecavir vs Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Chinese Subjects [NCT00986778]	Phase 4	0 participants (Actual)	Interventional	2009-12-31	Withdrawn(stopped due to Business Objectives Changed)
"A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Response-Guided-Therapy (RGT) Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients" [NCT02560649]	Phase 4	324 participants (Anticipated)	Interventional	2015-05-31	Active, not recruiting
A Phase IV Study of the Antiviral Activity and Safety of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen in Korea [NCT00393484]	Phase 4	122 participants (Actual)	Interventional	2007-02-28	Completed
"A Phase Randomized Open Labelled Controlled Dose Escalation Study of Repeated Administration of CYT107 (Glyco-r-hIL-7) Added on Antiviral Treatment and Vaccination in HBeAg-negative Chronic Hepatitis B-infected Patients" [NCT01027065]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2009-12-31	Active, not recruiting
Evaluation of the Pharmacokinetics, Safety, Tolerability and Efficacy of Entecavir (ETV) in Pediatric Subjects With Chronic Hepatitis B Virus (HBV) Infection Who Are HBeAg-Positive [NCT00423891]	Phase 1/Phase 2	64 participants (Actual)	Interventional	2007-06-30	Completed
An Open, Randomized Controlled Clinical Trial to Compare the Prophylactic Use or Preemptive Use of an Anti-viral Drug Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers [NCT02777814]	Phase 2	50 participants (Anticipated)	Interventional	2015-05-01	Recruiting
A Randomized, Prospective, Comparative Study of the Effectiveness of Prophylactic Entecavir Treatment for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation [NCT04942886]		164 participants (Anticipated)	Interventional	2021-08-21	Enrolling by invitation
Effects of Antiviral Therapy on HBV Reactivation and Liver Function After Hepatectomy for HBV-DNA Negative HBV-related Hepatocellular Carcinoma [NCT02829359]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2012-07-31	Completed
An Exploratory Study to Evaluate The Efficacy And Safety of HLX10, A Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein In Chronic Hepatitis B Patients [NCT04133259]	Phase 2	44 participants (Anticipated)	Interventional	2019-12-31	Recruiting
An Open, Randomized Controlled Clinical Trial to Compare the Prophylactic Use or Preemptive Use of an Anti-viral Drug Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers [NCT02777801]	Phase 2	50 participants (Anticipated)	Interventional	2015-06-30	Recruiting
Maintaining Antiviral Efficacy After Switching to Generic Entecavir, Baracle® in Patients Taking Baraclude® 1 mg for Antiviral Resistant Chronic Hepatitis B; A Noninferiority Study Assessing Non-detection Rate of Hepatitis B Virus DNA [NCT04069858]	Phase 4	40 participants (Actual)	Interventional	2016-12-01	Active, not recruiting
The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients After Curative Resection：a Randomized Controlled Trial [NCT04032860]	Phase 4	104 participants (Actual)	Interventional	2017-07-01	Active, not recruiting
Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients Who Receive Rituximab-containing Chemotherapy and Are Previously Infected With Hepatitis B Virus [NCT00931229]		202 participants (Actual)	Interventional	2009-06-30	Active, not recruiting
Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study [NCT01046799]	Phase 3	20 participants (Anticipated)	Interventional	2008-03-31	Completed
Randomized Clinical Study of Arabinoxylan Rice Bran (MGN-3/Biobran) for the Treatment of Hepatocellular Carcinoma and Hepatitis B and C Infection [NCT01018381]		130 participants (Actual)	Interventional	2006-06-30	Completed
A Phase 2, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Treatment With JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Patients [NCT04667104]	Phase 2	48 participants (Actual)	Interventional	2021-02-01	Completed
A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus [NCT02945982]	Phase 4	184 participants (Anticipated)	Interventional	2018-04-05	Recruiting
A Comparative Study of the Week 12 Antiviral Efficacy and Safety of Switching to Entecavir vs. Continuing Adefovir Treatment in Adults With Chronic Hepatitis B and Suboptimal Response to Adefovir [NCT00718887]	Phase 4	228 participants (Actual)	Interventional	2008-07-31	Completed
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis: A Multicenter, Real-world and Respective Study [NCT04160897]		4,000 participants (Anticipated)	Observational	2019-10-22	Enrolling by invitation
[NCT02588937]	Phase 4	76 participants (Anticipated)	Interventional	2015-10-31	Active, not recruiting
A Randomized, Open-label, 3-way Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics and Safety of Single-dose Cavir Tab. 0.5mg With Baraclude Tab. 0.5mg in Healthy Male Volunteers [NCT02586363]	Phase 1	30 participants (Anticipated)	Interventional	2015-11-30	Active, not recruiting
A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in Chronic Hepatitis B [NCT02615639]	Phase 1/Phase 2	450 participants (Anticipated)	Interventional	2015-11-30	Not yet recruiting
Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients [NCT02555943]	Phase 2/Phase 3	23 participants (Actual)	Interventional	2015-02-28	Completed
Randomized, Open-Labelled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B With Detectable HBV DNA [NCT00625560]	Phase 4	72 participants (Actual)	Interventional	2008-02-29	Completed
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Study in Healthy Subjects and Chronic Hepatitis B Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Freethiadine [NCT05391360]	Phase 1	128 participants (Actual)	Interventional	2021-10-11	Completed
A Single-center, Randomized, Double-blind, Single and Multiple Dosing, Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study [NCT04536532]	Phase 1/Phase 2	126 participants (Anticipated)	Interventional	2020-10-12	Suspended(stopped due to New investigational drug on the same target already in clinical trials)
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Combination With Entecavir in Comparison With Entecavir Alone in Patients With Chronic HBV Who Are HBeAg Positive [NCT04147208]	Phase 2	250 participants (Anticipated)	Interventional	2019-02-28	Recruiting
An Open-Label Phase 2 Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy : a Multicenter, Randomized, Positive Controlled Clin [NCT04157257]	Phase 2	60 participants (Anticipated)	Interventional	2019-07-26	Recruiting
Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Positive Chronic Hepatitis B [NCT00921180]	Phase 4	148 participants (Anticipated)	Interventional	2007-02-28	Recruiting
Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b [NCT02883647]		100 participants (Anticipated)	Observational	2014-01-31	Recruiting
A Study on Optimizing HBeAg Seroconversion in HBeAg Positive CHB Patients With Combination or Sequential Treatment of Pegylated Interferon Alpha-2a and Entecavir [NCT00940485]	Phase 4	200 participants (Actual)	Interventional	2009-04-30	Completed
Exploratory Study on Antiviral Therapy for Patients With Chronic Hepatitis B Virus Infection (Immune Tolerance Period) [NCT05382351]	Phase 2	238 participants (Anticipated)	Interventional	2022-05-10	Recruiting
Randomed and Double-blinded Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis [NCT02499562]	Phase 2	168 participants (Actual)	Interventional	2015-06-25	Completed
A Phase II Multi-center, Randomized, Single-blind, Placebo-controlled to Evaluate Safety and Efficacy of ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus [NCT05107778]	Phase 2	43 participants (Actual)	Interventional	2022-01-10	Active, not recruiting
Pegasys Plus Entecavir Versus Entecavir Alone for Hepatitis Be Antigen-Positive Chronic Hepatitis B [NCT00597259]	Phase 4	294 participants (Anticipated)	Interventional	2008-01-31	Recruiting
Augmenting Response to Entecavir Using a Temporary Peginterferon Alpha-2a add-on Strategy for the Treatment of HBeAg-positive Chronic Hepatitis B [NCT00877760]	Phase 4	184 participants (Actual)	Interventional	2009-08-31	Completed
A Pilot Trial of Simvastatin Alone and Added to Tenofovir or Entecavir for the Treatment of Chronic Hepatitis B [NCT00994773]	Phase 1	32 participants (Actual)	Interventional	2009-12-31	Completed
Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial [NCT00926757]	Phase 4	80 participants (Actual)	Interventional	2009-04-30	Completed
Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment-naïve Patients and Treated Patients With Chronic He [NCT06150014]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	2023-12-07	Recruiting
Entecavir and Peginterferon Alfa-2a Sequential Therapy Versus Peginterferon Alfa-2a Monotherapy for HBeAg Negative Chronic Hepatitis B [NCT00917761]	Phase 4	300 participants (Anticipated)	Interventional	2007-02-28	Recruiting
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment of Chronic Hepatitis B Subjects With Decompensated Liver Disease and in the P [NCT00298363]	Phase 2	112 participants (Actual)	Interventional	2006-04-30	Completed
Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B [NCT01906580]	Phase 4	105 participants (Anticipated)	Interventional	2011-07-31	Recruiting
A Randomized Phase 2a, Multicenter, Open-label Study Evaluating ABI-H0731-Containing Regimens in Patients With Chronic Hepatitis B [NCT04781647]	Phase 2	54 participants (Actual)	Interventional	2021-02-18	Terminated(stopped due to Study ABI-H0731-203 was terminated early by the study Sponsor for strategic reasons to prioritize research and development efforts on finite and curative HBV therapies.)
A Randomized, Placebo-Controlled, Open-label, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus [NCT02945956]	Phase 4	192 participants (Anticipated)	Interventional	2018-04-05	Recruiting
A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase [NCT00823550]	Phase 4	462 participants (Anticipated)	Interventional	2009-01-31	Active, not recruiting
A Phase Ib Dose-Escalation Study to Assess the Safety and Tolerability of DV-601 in Subjects With Chronic Hepatitis B on Concurrent Treatment With a Nucleoside Analogue [NCT01023230]	Phase 1	14 participants (Actual)	Interventional	2009-09-30	Completed
A Comparative Study of Entecavir vs. Adefovir Plus Lamivudine vs Combination Entecavir Plus Adefovir in Lamivudine-resistant Chronic Hepatitis B Subjects: The DEFINE Study [NCT00410202]	Phase 3	629 participants (Actual)	Interventional	2008-03-31	Completed
The Antiviral Efficacy of Entecavir in Chronic Hepatitis B Within the European Network of Excellence (VIRGIL) [NCT01323452]		418 participants (Actual)	Observational	2010-11-30	Completed
Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated With Nucleoside/Nucleotide Monotherapy for Patients With Chronic HBV Infection: The REALM Study [NCT00388674]		12,522 participants (Actual)	Observational	2006-12-18	Completed
A Comparative Study of Chronic Hepatitis B Subjects Treated With Entecavir Plus Tenofovir Combination Therapy vs. Entecavir Monotherapy in Adults Who Are Treatment-Naive to Nucleosides and Nucleotides: The BE-LOW Study [NCT00410072]	Phase 3	669 participants (Actual)	Interventional	2007-04-30	Completed
Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial [NCT01894269]	Phase 4	200 participants (Anticipated)	Interventional	2013-07-31	Recruiting
Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial [NCT01907230]	Phase 4	115 participants (Actual)	Interventional	2013-09-10	Active, not recruiting
A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.® and Baraclude Tab.® for HBeAG Chronic Hepatitis B [NCT01913431]	Phase 4	118 participants (Actual)	Interventional	2013-09-12	Completed
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Virus Reactivation in Patients With Non-Hodgkin Lymphoma on CHOP/R-CHOP: a Randomized Phase II Study [NCT01914744]	Phase 2	82 participants (Anticipated)	Interventional	2013-02-28	Recruiting
[NCT01918631]		36 participants (Actual)	Interventional	2013-08-31	Completed
Optimized Treatment and Regression of HBV-induced Liver Fibrosis [NCT01938781]	Phase 4	400 participants (Actual)	Interventional	2013-06-30	Completed
Optimized Treatment and Regression of HBV-induced Early Cirrhosis [NCT01938820]	Phase 4	82 participants (Actual)	Interventional	2013-06-30	Completed
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis [NCT01943617]	Phase 4	606 participants (Actual)	Interventional	2013-06-30	Completed
A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B [NCT04568265]	Phase 2	122 participants (Anticipated)	Interventional	2020-06-03	Recruiting
Randomized, Open-Labeled Study Evaluating the Antiviral Efficacy, Safety, and Tolerability of Continuing Lamivudine Therapy or Switching to Entecavir in Subjects With Chronic Hepatitis B Who Achieved Undetectable HBV DNA [NCT00625339]	Phase 4	72 participants (Actual)	Interventional	2008-02-29	Completed
A Comparative Study of the Efficacy and Safety of Entecavir and Tenofovir Versus Entecavir Alone in the Treatment of Hepatitis B DNA-positive Patients With Lymphomas [NCT04539119]	Phase 3	120 participants (Anticipated)	Interventional	2020-07-03	Recruiting
An Open-label, Dose-escalating Clinical Study to Evaluate the Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation (EP) in an Add-on Therapy With Entecavir in Chronic Hepatitis B Patients [NCT01641536]	Phase 1	9 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized, Open Labeled, Multicenter Study Comparing Entecavir Versus Lamivudine as Antiviral Prophylaxis for Patients With Hepatitis B Infection Undergoing Cytotoxic Chemotherapy for Malignant Tumors [NCT01580202]	Phase 3	180 participants (Actual)	Interventional	2012-04-30	Completed
A Randomized, Double-blind, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating HBeAg Positive Chronic Hepatitis B Patients [NCT01326546]	Phase 2	378 participants (Actual)	Interventional	2010-06-30	Completed
A Randomized, Open Label Study of the Effect of Peginterferon Alfa-2a (40KD) (PEGASYS®) Plus Entecavir (Baraclude®) Combination Therapy on Quantitative Changes in HBeAg in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B [NCT00614471]	Phase 4	219 participants (Actual)	Interventional	2007-08-31	Completed
Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial [NCT00663182]	Phase 4	200 participants (Anticipated)	Interventional	2008-01-31	Enrolling by invitation
A Randomized, Double-blinded, Placebo-controlled, Phase IIa Study of TQ-A3334 Combined With Entecavir in the Treatment of Untreated or HBV DNA Negative Subjects With Chronic Hepatitis B [NCT04180150]	Phase 2	12 participants (Anticipated)	Interventional	2019-11-18	Recruiting
Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects(Single Center, Single Arm, Open, Self - Control) [NCT04124081]	Phase 1	12 participants (Actual)	Interventional	2019-05-15	Completed
A Treatment Use Protocol of Entecavir in Subjects With Chronic Hepatitis B Infection Who Have Failed or Who Are Intolerant of Available Therapies [NCT00096811]		0 participants	Expanded Access	2003-09-30	No longer available
Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load [NCT01013272]		50 participants (Actual)	Interventional	2007-06-30	Completed
A Phase Ib, Open Label Study to Assess the Safety and Efficacy of Sequential Administration of P1101 and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection [NCT04638439]	Phase 1	20 participants (Anticipated)	Interventional	2021-12-31	Recruiting
A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B [NCT02908191]	Phase 1	86 participants (Actual)	Interventional	2016-11-30	Completed
The Use of Novel Hepatitis B Virus (HBV) Biomarkers to Detect Occult HBV Infection in Liver Donors Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc) in Liver Transplantation [NCT04199819]		100 participants (Anticipated)	Interventional	2022-01-01	Recruiting
A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B [NCT02881008]	Phase 1/Phase 2	48 participants (Actual)	Interventional	2012-11-14	Completed
Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase [NCT01833611]	Phase 4	130 participants (Anticipated)	Interventional	2008-09-30	Active, not recruiting
A Randomized Design Study to Compare the Efficacy of Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B: Role of Host and Viral Factors Associated With Treatment Response [NCT01243281]		126 participants (Anticipated)	Interventional	2011-03-31	Recruiting
A Multicenter, Open-label, Prospective Study to Evaluate Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Combination in Subjects With Multi-drug Resistant Chronic Hepatitis B Virus Infection [NCT01594905]	Phase 4	90 participants (Anticipated)	Interventional	2012-08-31	Active, not recruiting
Prospective Randomized Study for the Comparison of Adding Adefovir Dipivoxil and Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B [NCT00531167]	Phase 4	219 participants (Actual)	Interventional	2007-04-30	Completed
A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment [NCT01694264]	Phase 3	43 participants (Actual)	Interventional	2012-09-01	Terminated(stopped due to Delayed recruitment, unable to meet calculated sample size)
Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment [NCT01724723]	Phase 4	50 participants (Anticipated)	Interventional	2012-12-31	Not yet recruiting
Clinical and Basic Research of Relationship Between Hepatitis B Virus Quasi-Species Evolution and Function of Natural Killer Cells With Antiviral Therapy Response in Chronic Hepatitis B Patients [NCT03164889]		80 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to no enough participant can be enrolled)
The Efficacy and Safety of Switching to Vemliver Tab (Tenofovir Alafenamide Hemitartrate) From Entecavir in Chronic Hepatitis B Patients Who Pretreated With Entecavir; A Multi-Center, Randomized, Open-Label, Active-Controlled, Non-Inferiority, Phase IV Cl [NCT06000657]	Phase 4	196 participants (Anticipated)	Interventional	2023-07-28	Recruiting
Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy in Patients Who Have Been Treated With HB110E Hepatitis B DNA Vaccine [NCT01813487]		6 participants (Actual)	Interventional	2013-02-28	Completed
Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study) [NCT02360592]	Phase 4	94 participants (Actual)	Interventional	2013-06-30	Completed
HBV Viral Suppression by Entecavir in Adefovir Partial Responders [NCT00704106]		60 participants (Actual)	Observational	2008-05-31	Completed
Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma [NCT00555334]	Phase 4	200 participants (Anticipated)	Interventional	2007-11-30	Recruiting
A Randomized, Open-label Study of the Effect of Peginterferon Alfa-2a (40KD)(PEGASYS) in Combination With Adefovir or Entecavir on HBeAg Seroconversion in Patients With HBeAg Positive Chronic Hepatitis B [NCT00922207]	Phase 4	280 participants (Actual)	Interventional	2010-05-07	Completed
A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects [NCT03272009]	Phase 1	73 participants (Actual)	Interventional	2017-09-21	Completed
Entecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) (REHEB)：a Single Arm, Open Label, Multi-center Phase II Stud [NCT05453435]	Phase 2	84 participants (Anticipated)	Interventional	2022-07-15	Not yet recruiting
A Randomized, Open-label, Controlled, Multicenter, Exploratory Trial to Characterize the Results of Daily Oral Administration of Telbivudine (LDT600) 600 mg or Entecavir (ETV) 0.5 mg Given Over 12 Weeks on the Kinetics of Hepatitis B Virus (HBV) DNA in Ad [NCT00412529]	Phase 3	44 participants (Actual)	Interventional	2006-12-31	Completed
Entecavir Intensification for Persistent Hepatitis B Virus (HBV) Viremia in HIV-HBV Infection [NCT00662545]	Phase 4	10 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized, Double Blind, Placebo-controlled Phase 2b Study to Evaluate Efficacy, Pharmacokinetics, and Safety of 48-week Study Intervention With JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Viro [NCT04129554]	Phase 2	130 participants (Actual)	Interventional	2019-11-06	Completed
Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer [NCT05721300]		2,215 participants (Anticipated)	Interventional	2023-02-10	Recruiting
A Multicenter Controlled Open-label Trial of Evaluating Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate and Entecavir in Acute-on-chronic Liver Failure of Chronic Hepatitis B Patients [NCT03640728]		200 participants (Anticipated)	Observational	2019-01-25	Recruiting
Higher Risk of Kidney Function Decline With Entecavir Than Tenofovir Alafenamide in Patients With HBV Related Acute-on-chronic Liver Failure: Real-World Study [NCT05453448]		272 participants (Actual)	Interventional	2022-05-01	Completed
A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors [NCT03887702]	Phase 3	444 participants (Anticipated)	Interventional	2020-01-17	Active, not recruiting
Comparison Between Lamivudine and Entecavir Treatment in Patients With Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B. [NCT01627223]	Phase 4	17 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Slow progress in recruiting study patients)
A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment [NCT01639066]	Phase 4	102 participants (Actual)	Interventional	2012-09-25	Completed
A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment [NCT01639092]	Phase 4	88 participants (Actual)	Interventional	2012-09-28	Completed
A Phase 1, Blinded, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-64457744 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Ascending Doses [NCT05423106]	Phase 1	60 participants (Actual)	Interventional	2022-07-04	Terminated(stopped due to Strategic business decision, not due to safety concerns)
Switching to Tenofovir Disoproxil Fumarate vs. Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study [NCT01711567]	Phase 4	60 participants (Actual)	Interventional	2013-04-30	Completed
A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment [NCT01715987]		48 participants (Actual)	Observational	2012-10-31	Terminated
Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma [NCT01765231]	Phase 4	190 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy [NCT01768195]	Phase 4	80 participants (Anticipated)	Interventional	2013-01-31	Recruiting
A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study [NCT01829685]	Phase 4	360 participants (Anticipated)	Interventional	2013-03-31	Active, not recruiting
The Incidence of Lactic Acidosis During Entecavir Treatment in Chronic Hepatitis B Patients With Severe Cirrhosis or Hepatic Failure [NCT01354652]	Phase 4	5 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Tenofovir has become available in Korea.)
A Prospective Study to Investigate the Relationship Between Hepatitis B Surface Antigen (HBsAg) Loss and the Dynamics in Host and Viral Markers After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment in Chronic Hepatitis B E-antigen Negative Patients [NCT05550519]	Early Phase 1	0 participants (Actual)	Interventional	2022-10-31	Withdrawn(stopped due to Sponsor decision after reevaluation of strategy in the context of recruitment timelines projection)
Study on Therapeutic Effects and Safety of Three Types of Nucleotide/Nucleoside Analogues in Patients With Chronic Hepatitis b [NCT04195074]		300 participants (Anticipated)	Interventional	2019-01-01	Recruiting
Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor [NCT02973646]	Phase 4	100 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Efficacy Comparison Between Two Kind of Chinese Herbal Formulas on Traditional Chinese Medicine Syndromes Among Chronic Hepatitis Patients [NCT03018821]		250 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) vs Lamivudine in Adults With Chronic Hepatitis B Infection [NCT01022801]	Phase 2	120 participants (Anticipated)	Interventional	2003-08-31	Completed
Stopping Antiviral Treatment and Subsequent Flare in Chronic Hepatitis B Infection: Immunological and Virological Profiling [NCT04431245]		54 participants (Anticipated)	Observational	2021-06-01	Active, not recruiting
Safety and Efficacy of Finite Versus Continuous Nucleos(t)Ide Analogues Therapy in Patients With Chronic Hepatitis B: A Multicenter Randomized Controlled Trial [NCT05793268]		360 participants (Anticipated)	Interventional	2022-12-20	Active, not recruiting
A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects [NCT03239353]	Phase 1	40 participants (Actual)	Interventional	2017-10-20	Completed
A Preliminary Assessment of Safety and Antiviral Activity of Open-label Entecavir in Subjects With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials [NCT01438424]	Phase 2	1,053 participants (Actual)	Interventional	2001-01-31	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, [NCT02452528]	Phase 2	4 participants (Actual)	Interventional	2015-08-31	Terminated(stopped due to Company decision to discontinue trial)
A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH) [NCT02577029]	Phase 2	79 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Company decision to discontinue trial)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, [NCT02604199]	Phase 2	58 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Company decision to discontinue trial)
A Randomized, Open-label Trial Comparing Telbivudine vs, Entecavir in Reducing Serum HBsAg Levels in Patients With HBeAg-positive Chronic Hepatitis B Who Have Achieved Serum HBV DNA Undetectability by Preceding Entecavir Treatment [NCT01595685]	Phase 3	98 participants (Actual)	Interventional	2012-05-31	Completed
A Randomized, Multicenter, Prospective Study to Compare Antiviral Efficacy and Safety of Switching to ETV Plus TDF Versus Maintaining LAM/LDT Plus ADF Combination in CHC With PVR to LAM/LDF Plus ADF Combination Rescue Therapy for YMDD Mutation [NCT01597934]	Phase 4	104 participants (Anticipated)	Interventional	2012-08-31	Active, not recruiting
The Efficacy of Peg-interferon α-2a in HBeAg (+) Chronic Hepatitis B Patients Who Have Been Treated by Entecavir for 48 Weeks But Without HBeAg Loss [NCT01599130]		60 participants (Anticipated)	Interventional	2012-07-31	Not yet recruiting
Adjuvant Entecavir or Tenofovir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection [NCT02650271]	Phase 3	240 participants (Anticipated)	Interventional	2021-02-02	Recruiting
Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B [NCT01925820]	Phase 4	540 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B [NCT01926288]	Phase 4	287 participants (Actual)	Interventional	2008-10-31	Completed
SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL) [NCT01928511]	Phase 4	254 participants (Actual)	Interventional	2014-01-31	Completed
Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B [NCT02726789]	Phase 2	5 participants (Actual)	Interventional	2012-10-31	Completed
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir [NCT05423834]		1,800 participants (Anticipated)	Observational [Patient Registry]	2022-09-01	Active, not recruiting
The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial. [NCT03062813]	Phase 4	112 participants (Anticipated)	Interventional	2017-02-01	Recruiting
A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Patients With Chronic Hepatitis B [NCT03577171]	Phase 2	25 participants (Actual)	Interventional	2018-06-19	Completed
A Phase 2a Open-label Study of the Oral Farnesoid X Receptor (FXR) Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B (CHB) Patients in Combination With Pegylated Interferon alpha2a (Peg-IFN) Alone and With Entecavir (ETV) [NCT04365933]	Phase 2	20 participants (Actual)	Interventional	2020-05-25	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After a Single Intravenous Dose of ARC-520 in Combination With Entecavir in Patients Wi [NCT02065336]	Phase 2	58 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to Company decision to discontinue trial)
Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation [NCT02417207]	Phase 4	60 participants (Anticipated)	Interventional	2015-04-30	Not yet recruiting
A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Patients Wit [NCT02391805]	Phase 2	31 participants (Actual)	Interventional	2015-05-17	Completed
A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study [NCT01834508]	Phase 4	600 participants (Anticipated)	Interventional	2013-03-31	Active, not recruiting
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis [NCT01720238]		621 participants (Actual)	Observational	2012-03-31	Active, not recruiting
A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus [NCT02241590]	Phase 4	700 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Study on Therapeutic Effects and Safety of Three Types of Nucleotide/Nucleoside Analogues in Patients With Hepatitis b Virus Related Compensated Cirrhosis [NCT04196998]		150 participants (Anticipated)	Interventional	2019-01-01	Recruiting
A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC [NCT03084250]	Phase 4	150 participants (Anticipated)	Interventional	2017-03-10	Active, not recruiting
Hellenic Multicenter Real-life Clinical Study for Bulevirtide Therapy in Chronic Hepatitis D: HERACLIS-BLV [NCT05928000]		80 participants (Anticipated)	Observational [Patient Registry]	2023-05-01	Recruiting
A Prospective Randomized Controlled Trial of Tenofovir and Entecavir in the Treatment of Long-term Prognosis in Patients With Hepatitis B-related Hepatocellular Carcinoma After Curative Resection [NCT04392700]	Phase 3	706 participants (Anticipated)	Interventional	2019-07-25	Recruiting
A Multi Center, Phase IIIb Study to Evaluate the Efficacy of Response Guided Therapy Using Quantitative HBsAg Measurement in Patient With HBeAg Positive Chronic Hepatitis B: [NCT01456312]	Phase 4	200 participants (Anticipated)	Interventional	2012-09-30	Recruiting
A Multi-center, Open-label, Long-term Extension Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients [NCT03780543]	Phase 2	92 participants (Actual)	Interventional	2018-12-20	Terminated(stopped due to Sponsor decision)
Role of Nucleoside Analogue in Preventing Clinical Reactivation of HBV in HCV/HBV Co-infected Patients Receiving DAA Therapy for Chronic Hepatitis C [NCT04405011]		60 participants (Anticipated)	Interventional	2018-08-01	Recruiting
A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV [NCT02241616]	Phase 4	350 participants (Anticipated)	Interventional	2014-09-30	Recruiting
A Randomized, Open-label, Multi-part Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers [NCT03032536]	Phase 1	54 participants (Actual)	Interventional	2017-01-31	Terminated(stopped due to Sponsor decision.)
Alterations in the Intestinal Microbiome and Metabolic Profile of Patients With Cirrhosis Supplemented With Lactulose, Clostridium Butyricum, and Bifidobacterium Longum Infantis: a Randomized Placebo-controlled Trial [NCT05687409]	Phase 4	120 participants (Actual)	Interventional	2019-11-24	Completed
A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection [NCT00605384]	Phase 3	4 participants (Actual)	Interventional	2008-08-31	Terminated(stopped due to Business Objectives Have Changed)
Prospective Trial of Entecavir for Chronic Hepatitis B in Hepatocellular Carcinoma Patients Underwent Radiofrequency Ablation Therapy [NCT01270178]		420 participants (Anticipated)	Observational	2011-01-31	Not yet recruiting
A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B [NCT03357822]	Phase 4	2,000 participants (Anticipated)	Interventional	2018-01-25	Recruiting
The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B [NCT03349008]	Phase 4	480 participants (Anticipated)	Interventional	2017-11-25	Not yet recruiting
The Efficacy and Safety of Tenofovir Alafenamide Fumarate Compared With Other Nucleoside Analogues (Acid) to Treat Patients With Low-level Viremia of HBV [NCT04501224]		200 participants (Anticipated)	Interventional	2020-08-03	Recruiting
Study to Compare Virological Response to 0.5 mg Daily Versus 1.0 mg Daily Oral Doses of Entecavir in Chronic Hepatitis B Virus Infection Related Decompensated Cirrhosis [NCT03345498]		32 participants (Actual)	Observational	2017-01-01	Completed
Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus [NCT02482272]	Phase 4	90 participants (Anticipated)	Interventional	2015-05-31	Recruiting
[NCT01892241]	Phase 3	74 participants (Actual)	Interventional	2010-01-31	Completed
PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab [NCT02523547]	Phase 4	134 participants (Anticipated)	Interventional	2015-01-31	Recruiting
[NCT00035789]	Phase 3	0 participants	Interventional	2001-11-30	Completed
[NCT00035633]	Phase 3	0 participants	Interventional	2001-12-31	Completed
Study of the Drug Interaction of EYP001a With Entecavir in Healthy Subjects [NCT03469583]	Phase 1	16 participants (Actual)	Interventional	2018-02-12	Completed
Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy [NCT03366571]		600 participants (Anticipated)	Observational	2016-01-31	Active, not recruiting
Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients [NCT03332329]	Phase 4	15 participants (Actual)	Interventional	2015-12-01	Active, not recruiting
Utilization of Hepatitis B Virus Nucleic Acid Test Positive Donors for Hepatitis B Vaccinated Lung Transplant Candidates [NCT05404919]	Phase 2	10 participants (Anticipated)	Interventional	2022-09-06	Recruiting
Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir Combination Therapy-Multicenter Randomized [NCT03236610]	Phase 3	112 participants (Anticipated)	Interventional	2016-01-01	Recruiting
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial [NCT03933384]	Phase 4	420 participants (Anticipated)	Interventional	2019-08-19	Recruiting
A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase [NCT02263079]	Phase 3	62 participants (Actual)	Interventional	2014-06-16	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00065507 (26) [back to overview]	Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48
NCT00065507 (26) [back to overview]	Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48
NCT00065507 (26) [back to overview]	Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period
NCT00065507 (26) [back to overview]	Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data
NCT00065507 (26) [back to overview]	Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48
NCT00065507 (26) [back to overview]	Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24
NCT00065507 (26) [back to overview]	Mean Change From Baseline in Total Bilirubin Through Week 48
NCT00065507 (26) [back to overview]	Mean Change From Baseline in Prothrombin Time Through Week 48
NCT00065507 (26) [back to overview]	Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48
NCT00065507 (26) [back to overview]	Improvement or No Worsening in MELD Score Through Week 48
NCT00065507 (26) [back to overview]	Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL
NCT00065507 (26) [back to overview]	Change From Baseline in Platelet Count Through Week 48
NCT00065507 (26) [back to overview]	Change From Baseline in Child-Pugh Score Through Week 48
NCT00065507 (26) [back to overview]	Change From Baseline in Albumin Through Week 48
NCT00065507 (26) [back to overview]	>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48
NCT00065507 (26) [back to overview]	Change From Baseline in HBV DNA by PCR at Week 48
NCT00065507 (26) [back to overview]	Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24
NCT00065507 (26) [back to overview]	Participants Achieving Albumin Normalization Through Week 48
NCT00065507 (26) [back to overview]	Participants Achieving Platelet Count Normalization Through Week 48
NCT00065507 (26) [back to overview]	Participants Achieving Prothrombin Time Normalization Through Week 48
NCT00065507 (26) [back to overview]	Participants Achieving Total Bilirubin Normalization Through Week 48
NCT00065507 (26) [back to overview]	Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48
NCT00065507 (26) [back to overview]	Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48
NCT00065507 (26) [back to overview]	Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up
NCT00065507 (26) [back to overview]	Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment
NCT00065507 (26) [back to overview]	Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48
NCT00096785 (10) [back to overview]	HBV DNA Viral Kinetics - Spline Model
NCT00096785 (10) [back to overview]	HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections
NCT00096785 (10) [back to overview]	HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate
NCT00096785 (10) [back to overview]	Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs
NCT00096785 (10) [back to overview]	Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths
NCT00096785 (10) [back to overview]	Alanine Aminotransferase (ALT) Normalization
NCT00096785 (10) [back to overview]	Change From Baseline in HBV DNA by PCR Assay at Week 48
NCT00096785 (10) [back to overview]	Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12
NCT00096785 (10) [back to overview]	HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus
NCT00096785 (10) [back to overview]	Viral Load Undetectable (HBV DNA <300 Copies/mL)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 96 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 96
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 168
NCT00298363 (38) [back to overview]	Median Change in MELD Score From Baseline at Week 144
NCT00298363 (38) [back to overview]	In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline
NCT00298363 (38) [back to overview]	Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL
NCT00298363 (38) [back to overview]	Percent Probability of Tolerability Failure
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With an Increase in CPT Score of ≥ 2 Points at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With Baseline ADV-R + LAM-R Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized Alanine Aminotransferase (ALT) (for Subjects With Elevated ALT at Baseline) at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Normalized ALT (for Subjects With Elevated ALT at Baseline) at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With Hepatitis B Early Antigen (HBeAg) Loss and HBeAg Seroconversion at Week 48 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With Only Baseline Adefovir Dipivoxil Resistance (ADV-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Only Baseline Lamivudine-resistance (LAM-R) Mutations Achieving HBV DNA < 400 Copies/mL by 168 Weeks
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 48
NCT00298363 (38) [back to overview]	Percentage of Participants With Plasma HBV DNA < 400 Copies/mL at Week 96
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 144 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 168 (for Participants Who Were HBeAg Positive at Baseline)
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 144
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 168
NCT00298363 (38) [back to overview]	Percentage of Participants With HBsAg Loss and HBsAg Seroconversion at Week 96
NCT00298363 (38) [back to overview]	Median Change in Model for End-Stage Liver Disease (MELD) Score From Baseline at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 48 (for HBeAg-positive Participants Only)
NCT00371150 (13) [back to overview]	Percentage of Participants With HBV DNA by PCR Category at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants With Confirmed HBeAg Loss at Week 48 (for HBeAg-positive Participants Only)
NCT00371150 (13) [back to overview]	Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to Adverse Events
NCT00371150 (13) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants With Virologic Rebound Through Week 48 While on Continued Dosing With ETV
NCT00371150 (13) [back to overview]	Mean log10 Reduction From Baseline in HBV DNA at Week 48
NCT00371150 (13) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48
NCT00371150 (13) [back to overview]	Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) : Serum Chemistry
NCT00371150 (13) [back to overview]	Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF): Hematology
NCT00388674 (6) [back to overview]	Number of Participants With Liver-related HBV Disease Progression
NCT00388674 (6) [back to overview]	Number of Participants With HCC Malignant Neoplasm
NCT00388674 (6) [back to overview]	Number of Participants With Adjudicated Overall Malignant Neoplasms
NCT00388674 (6) [back to overview]	Number of Participants With Non-HCC Malignant Neoplasm
NCT00388674 (6) [back to overview]	Number of Deaths
NCT00388674 (6) [back to overview]	Number of Participants With Liver-related Death
NCT00393484 (14) [back to overview]	Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 96
NCT00393484 (14) [back to overview]	Number of Participants With Hepatitis B Virus (HBV) DNA <10^3, <10^4, or < 10^5 Copies/mL by Polymerase Chain Reaction (PCR) Assy at Weeks 24, 48, and 96
NCT00393484 (14) [back to overview]	Number of Participants With Normalization of Serum Alanine Aminotransferase (ALT) Levels at Weeks 24, 48, and 96
NCT00393484 (14) [back to overview]	Number of Participants With Viral Rebound and Drug-resistant Hepatitis B Virus (HBV) DNA Mutations at Week 96
NCT00393484 (14) [back to overview]	Percentage of Participants With a Virologic Response as Defined by Undetectable Hepatitis B Virus DNA at Weeks 48, 96, 144, 192, and 240
NCT00393484 (14) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 240
NCT00393484 (14) [back to overview]	Mean Laboratory Test Values for Alanine Aminotransferase (ALT) at Week 24
NCT00393484 (14) [back to overview]	Number of Participants With Clinically or Statistically Significant Changes in Vital Sign Measurements at Week 24
NCT00393484 (14) [back to overview]	Number of Participants With Virologic Rebound at Week 24
NCT00393484 (14) [back to overview]	Percentage of Participants Who Achieved a Virologic Response at Week 24
NCT00393484 (14) [back to overview]	Mean Log10 Reduction From Baseline in Hepatitis B Virus (HBV) DNA at Weeks 24, 48, 96, 144, 192, and 240
NCT00393484 (14) [back to overview]	Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Most Common AEs, and Grade 3/4 AEs at Week 24
NCT00393484 (14) [back to overview]	Number of Participants With Elevations in Alanine Transaminase (ALT) and Aspartate Aminoaminase (AST) Levels, Elevations in ALT and AST Levels,Simultaneous Elevations in ALT and Total Bilirubin Levels, and ALT Flares at Week 24
NCT00393484 (14) [back to overview]	Number of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results by World Health Organization (WHO) Criteria at Week 24
NCT00395018 (15) [back to overview]	Percentage of Participants With HBeAg Loss at Week 72 (for HBeAg-positive Participants)
NCT00395018 (15) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 72 (for HBeAg-positive Participants)
NCT00395018 (15) [back to overview]	Percentage of Participants With HBsAg Loss at Week 72
NCT00395018 (15) [back to overview]	Percentage of Participants With HBsAg Recurrence At Week 72
NCT00395018 (15) [back to overview]	Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) => 50 IU/mL by Polymerase Chain Reaction (PCR) at Week 72
NCT00395018 (15) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 72
NCT00395018 (15) [back to overview]	Number of Participants With HBV DNA by PCR >= 50 IU/mL Through Week 72
NCT00395018 (15) [back to overview]	Distribution of ALT Levels Through 72 Weeks: Overall
NCT00395018 (15) [back to overview]	Number of Participants With Liver Rejection Through Week 72
NCT00395018 (15) [back to overview]	Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment (OF) Follow-up: Serum Chemistry (All Grades)
NCT00395018 (15) [back to overview]	Number of Participants With Laboratory Abnormalities On-treatment (OT) and Off-Treatment Follow-up(OF): Hematology (All Grades)
NCT00395018 (15) [back to overview]	Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations From Study Drug Due to AEs (On-treatment [OT] and Off-treatment Follow-up [OF])
NCT00395018 (15) [back to overview]	Number of Participants With Re-transplantation Through Week 72
NCT00395018 (15) [back to overview]	Total Bilirubin at Week 72
NCT00395018 (15) [back to overview]	Prothrombin Time (PT) at Week 72
NCT00410072 (16) [back to overview]	Percentage of Participants With HBeAg Seroconversion [( at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved HBV DNA Levels
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved HBV DNA Levels
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved HBV DNA Levels <50 IU/mL by PCR at Week 48 and Week 96 by Hepatitis B e Antigen (HBeAg) Status
NCT00410072 (16) [back to overview]	Number of Participants With Virologic Breakthrough at Week 48
NCT00410072 (16) [back to overview]	Number of Participants With HBV Resistance Through Week 48
NCT00410072 (16) [back to overview]	Number of Participants With HBV Resistance at Week 96
NCT00410072 (16) [back to overview]	Number of Participants With HBV DNA in Relevant Categories at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Number of Participants With Adverse Events, Serious Adverse Events, and Discontinuations From Study Drug Due to Adverse Events or Laboratory Abnormalities
NCT00410072 (16) [back to overview]	Mean Log 10 HBV DNA at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96
NCT00410072 (16) [back to overview]	Number of Participants With Virologic Breakthrough at Week 96
NCT00410072 (16) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 48 and 96
NCT00410072 (16) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Weeks 48 and 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) > 1 x Upper Limit of Normal (ULN) at Baseline Who Achieve ALT Normalization at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Quantitation (LOQ = 29 IU/mL [Approximately 169 Copies/mL]) at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants Who Achieve HBV DNA < Lower Limit of Detection (LOD = 10 IU/mL [Approximately 58 Copies/mL]) at Week 48
NCT00410202 (25) [back to overview]	Change in Mean log10 From Baseline in HBV DNA at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With HBV DNA < 50 IU/mL (Approximately 300 Copies/mL) by PCR at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48
NCT00410202 (25) [back to overview]	Change in Mean log10 From Baseline in HBV DNA at Week 48
NCT00410202 (25) [back to overview]	Cumulative Probability of Emergent Genotypic Resistance at Year 1
NCT00410202 (25) [back to overview]	Cumulative Probability of Emergent Genotypic Resistance at Year 2
NCT00410202 (25) [back to overview]	Number of Participants With Laboratory Abnormalities: Hematology
NCT00410202 (25) [back to overview]	Number of Participants With Laboratory Abnormalities: Serum Chemistry
NCT00410202 (25) [back to overview]	Participants With Adverse Events (AE), Serious Adverse Events (SAE), and Discontinuations Due to Adverse Events or Laboratory Abnormalities During Treatment
NCT00410202 (25) [back to overview]	Percentage of Participants With HBV DNA by PCR Category at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBV DNA by PCR Category at Week 96
NCT00410202 (25) [back to overview]	Percentage of Participants With Confirmed HBeAg Loss at Week 48 (Treated HBeAg Positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With Confirmed HBeAg Loss at Week 96 (Treated HBeAg Positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With HBsAg Seroconversion at Week 48
NCT00410202 (25) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 48 (Treated HBeAg-positive Participants Only)
NCT00410202 (25) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 96 (Treated HBeAg-positive Participants Only)
NCT00412529 (8) [back to overview]	The Area Under the Curve (AUC) of HBV DNA Change.
NCT00412529 (8) [back to overview]	Characterization of Very Early Viral Kinetics: Estimation of Viral Clearance
NCT00412529 (8) [back to overview]	Characterization of Very Early Viral Kinetics: Estimation of the Rate of Infected Cell Loss
NCT00412529 (8) [back to overview]	Characterization of Very Early Viral Kinetics: Estimation of the Efficiency Factor of Blocking Virus Production
NCT00412529 (8) [back to overview]	Change in Alanine Aminotransferase (ALT) Levels
NCT00412529 (8) [back to overview]	Number of Patients Who Are Polymerase Chain Reaction (PCR) Negative
NCT00412529 (8) [back to overview]	Change in Mean Hepatitis B Virus (HBV) DNA Levels
NCT00412529 (8) [back to overview]	Change in Mean HBV DNA Level
NCT00423891 (22) [back to overview]	Number of Participants With HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With HBV DNA Less Than Lower Limit of Quantification (LLQ) for the Roche COBAS TaqMan - HPS Assay Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With HBV DNA Less Than Lower Limit of Detection (LLD) for the Roche COBAS TaqMan - HPS Assay at Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants Who Had a Protocol Defined Response (PDR) Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Plus HBeAg Seroconversion Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With Chemistry Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With Electrolyte Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With HB s Antigen (HBsAg) Seroconversion Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With HBV DNA by PCR Categories at Weeks 48 and 96 in Treated Participants
NCT00423891 (22) [back to overview]	Alanine Aminotransferase (ALT) Normalization From Baseline Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Mean Apparent Total Body Clearance (CLT/F) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
NCT00423891 (22) [back to overview]	Mean Area Under the Concentration-Time Curve in One Dosing Interval [AUC(TAU)] of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
NCT00423891 (22) [back to overview]	Mean Log10 Change From Baseline in HBV DNA Using Roche COBAS TaqMan - HPS Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Mean Maximum Observed Plasma Concentration (Cmax) and Mean Trough Observed Plasma Concentration (Cmin) of Entecavir in LVD-naive and LVD-experienced Participants, by Age Cohort
NCT00423891 (22) [back to overview]	Median Time of Maximum Observed Plasma Concentration (Tmax) in LVD-naive and LVD-experienced Participants, by Age Cohort
NCT00423891 (22) [back to overview]	Number of Participants With a Combination of ALT Normalization and HBV DNA Less Than 50 IU/mL, Without HBeAg Seroconversion, Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With Serious Adverse Events (SAE) and Discontinuations Due to Adverse Events (AEs) - On Treatment
NCT00423891 (22) [back to overview]	Number of Participants With Hepatitis B s Antigen (HBsAg) Loss Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With Hepatitis B e Antigen Seroconversion Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With Hepatitis B e Antigen (HBeAg) Loss Through Week 96 in Treated Participants
NCT00423891 (22) [back to overview]	Number of Participants With Hematology Laboratory Abnormalities (Grades 1 - 4) - On Treatment - Treated Participants
NCT00605384 (1) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities
NCT00662545 (5) [back to overview]	Incidence of Permanent Discontinuation Due to Toxicity
NCT00662545 (5) [back to overview]	Incidence of New Hepatic Decompensation( Ascites, Variceal Hemorrhage, Encephalopathy)
NCT00662545 (5) [back to overview]	Incidence of ALT Flares
NCT00662545 (5) [back to overview]	HIV RNA < 75 Copies/ml
NCT00662545 (5) [back to overview]	Hepatitis B Virus (HBV) DNA
NCT00718887 (9) [back to overview]	Mean log10 Reduction From Baseline in Serum HBV DNA Level by Polymerase Chain Reaction Testing
NCT00718887 (9) [back to overview]	Percentage of Participants With Loss of Hepatitis B e Antigen (HBeAg) and Hepatitis B e (HBe) Seroconversion
NCT00718887 (9) [back to overview]	Percentage of Participants With Grade 3 or 4 Abnormalities in Laboratory Test Results
NCT00718887 (9) [back to overview]	Percentage of Participants Who Achieved Normalization of Alanine Aminotransferase (ALT)
NCT00718887 (9) [back to overview]	Number of Participants With Hepatitis B s Surface Antibody (HBsAG) Loss and HBsAG Seroconversion
NCT00718887 (9) [back to overview]	Number of Participants With Genotypic Resistance to Entecavir
NCT00718887 (9) [back to overview]	Number of Participants With Adverse Events, Treatment-related AEs, Serious Adverse Events (SAEs), Treatment-related SAEs, Death as Outcome, Discontinuations Due to AEs, and Abnormalities in Laboratory Test Results (LTR) Leading to Discontinuation
NCT00718887 (9) [back to overview]	Percentage of Participants Who Achieved an HBV DNA Level <50 IU/mL at Week 48 by Polymerase Chain Reaction Testing
NCT00718887 (9) [back to overview]	Percentage of Participants Who Achieved a Hepatitis B Virus (HBV) DNA Level <50 IU/mL at Week 12 by Polymerase Chain Reaction Testing
NCT00922207 (7) [back to overview]	Percentage of Participants Who Were HBeAg Negative
NCT00922207 (7) [back to overview]	Percentage of Participants With Combined Response
NCT00922207 (7) [back to overview]	Percentage of Participant Who Were Both Hepatitis B Surface Antigen (HBsAg) Negative and Hepatitis B Surface Antibody (Anti-HBs/HBsAb) Positive
NCT00922207 (7) [back to overview]	Percentage of Participant With Normal Alanine Aminotransferase (ALT) Levels
NCT00922207 (7) [back to overview]	Change From Baseline in Hepatitis B Virus Deoxyribonucleic Acid (HBV DNA) Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
NCT00922207 (7) [back to overview]	Percentage of Participants With Hepatitis B e-Antigen (HBeAg) Seroconversion at 100 Weeks After Start of Treatment
NCT00922207 (7) [back to overview]	Change From Baseline in HBsAg Levels at Weeks 4, 8, 16, 28, 40, 52, 64, 76, 88, and 100
NCT00940485 (10) [back to overview]	Percentage of Participants With Hepatitis B Virus - Deoxyribonucleic Acid <1000 Copies/ Millilitre at Week 48
NCT00940485 (10) [back to overview]	Percentage of Participants With Loss of Hepatitis B Envelope Antigen at Week 48
NCT00940485 (10) [back to overview]	Quantitative Change in Mean Hepatitis B Envelope Antigen Over Time
NCT00940485 (10) [back to overview]	Quantitative Change in Mean Hepatitis B Surface Antigen Change Over Time
NCT00940485 (10) [back to overview]	Number of Participants With Laboratory Abnormalities Which Were Captured as an Adverse Event
NCT00940485 (10) [back to overview]	Percentage of Participants With Normalized Alanine Aminotransferase at Week 48
NCT00940485 (10) [back to overview]	Number of Participants With Incidence of Adverse Events and Serious Adverse Events
NCT00940485 (10) [back to overview]	Percentage of Participants With Hepatitis B Envelope Antigen Seroconversion at Week 48
NCT00940485 (10) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen Loss at Week 48
NCT00940485 (10) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen Seroconversion at Week 48
NCT01023217 (1) [back to overview]	Complete Virologic Response (CVR, Serum HBV DNA Undetectable by PCR or Less Than 60 IU/mL)
NCT01063036 (11) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBsAg-Positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 24, 48, 96 - Treated Population Who Were HBsAg-Positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg Positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With HBV DNA Less Than the Lower Limit of Detection (LLD) at Weeks 24, 48, and 96 - Treated Population
NCT01063036 (11) [back to overview]	Percentage of Participants With a Virologic Response at Week 24 and at Week 96 - Treated Population
NCT01063036 (11) [back to overview]	Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) on Treatment, and Discontinuation of Study Drug Due to Adverse Events (AE) - Treated Population
NCT01063036 (11) [back to overview]	Number of Participants With Emergence of Genotypic Resistance to Study Drugs at Weeks 48 and 96- Treated Population
NCT01063036 (11) [back to overview]	Percentage of Participants With HBe Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg-positive at Baseline
NCT01063036 (11) [back to overview]	Percentage of Participants With a Virologic Response at Week 48 - Treated Population
NCT01063036 (11) [back to overview]	Change From Baseline in Mean log10 HBV DNA at Weeks 12, 24, 48, and 96 - Treated Evaluable Population
NCT01063036 (11) [back to overview]	Number of Participants on Treatment With Study Drug With Laboratory Test Abnormalities Meeting Selected Criteria on Treatment - Treated Population
NCT01079806 (16) [back to overview]	Percentage of Participants Who Achieved a Combination of Hepatitis B Virus (HBV) DNA Suppression and Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48
NCT01079806 (16) [back to overview]	Histological Analysis (Percentage) Among Participants With Available Liver Biopsy Data
NCT01079806 (16) [back to overview]	Percentage of Participants With HBeAg Seroconversion (Undetectable HBeAg and Presence of Anti-HBeAb) up to Week 96
NCT01079806 (16) [back to overview]	Percentage of Participants With HBeAg Seroconversion on ETV Over-time at Week 96 (All ETV Cohort)
NCT01079806 (16) [back to overview]	Percentage of Participants With Hepatitis B e Antigen (HBeAg) Seroconversion at Week 48 (Undetectable HBeAg and Presence of Anti-HBeAb)
NCT01079806 (16) [back to overview]	Percentage of Participants With Hepatitis B Virus (HBV) DNA <50 IU/mL at Week 48
NCT01079806 (16) [back to overview]	Percentage of Participants With Hepatitis B Virus DNA
NCT01079806 (16) [back to overview]	Percentage of Participants With Serum Alanine Aminotransferase ≤1*Upper Limit of Normal at Week 48
NCT01079806 (16) [back to overview]	Number of Participants With Adverse Events (Including Palatability Issues), SAEs, Discontinuous Due to Adverse Events, and HBV Disease Progression Through Week 48
NCT01079806 (16) [back to overview]	Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4)
NCT01079806 (16) [back to overview]	Number of Participants With Laboratory Test Results Meeting the Criteria for Abnormality (Grades 1-4) (Continued)
NCT01079806 (16) [back to overview]	Percentage of Participants Who Achieved Sustained HBeAg Seroconversion During Off-treatment Follow up Among Participants Who Achieved HBeAg Seroconversion at End of Dosing (EOD).
NCT01079806 (16) [back to overview]	Percentage of Participants Who Maintained HBeAg Seroconversion at Week 96 (End of Blinded Therapy) Among Participants With HBeAg Seroconversion at Week 48
NCT01079806 (16) [back to overview]	Percentage of Participants With Death as Outcome, Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Related AEs, Grade 2-4 Related AEs, Grade 3-4 AEs, Malignancies, ALT Flares, and Hepatic Disease Progression Through Week 96
NCT01079806 (16) [back to overview]	Percentage of Participants With HbeAg Loss at Weeks 48 and 96
NCT01079806 (16) [back to overview]	Percentage of Participants With HbeAg Loss at Weeks 48 and 96
NCT01326546 (1) [back to overview]	Percentage of Participants With HBeAg Seroconversion at Week 48
NCT01354652 (2) [back to overview]	Overall OLT-free Survival
NCT01354652 (2) [back to overview]	Incidence of Elevated Venous Lactate Levels More Than 2 mmol/L of Any Etiology
NCT01368497 (24) [back to overview]	Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss
NCT01368497 (24) [back to overview]	Proportion of Participants With Hepatitis B Surface Antigen (HBsAg) Loss
NCT01368497 (24) [back to overview]	Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss & Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels ≤1,000 International Units (IU) Per Milliliter (mL)
NCT01368497 (24) [back to overview]	Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss
NCT01368497 (24) [back to overview]	Proportion of Participants With Hepatitis B e Antigen (HBeAg) Loss
NCT01368497 (24) [back to overview]	Proportion of Participants With HBV DNA ≤1000 IU/mL
NCT01368497 (24) [back to overview]	Proportion of Participants With HBV DNA ≤1000 IU/mL
NCT01368497 (24) [back to overview]	Proportion of Participants With HBV DNA < 20 IU/mL
NCT01368497 (24) [back to overview]	Proportion of Participants With HBV DNA < 20 IU/mL
NCT01368497 (24) [back to overview]	Proportion of Participants With HBsAg Seroconversion
NCT01368497 (24) [back to overview]	Proportion of Participants With HBsAg Seroconversion
NCT01368497 (24) [back to overview]	Proportion of Participants With HBeAg Seroconversion
NCT01368497 (24) [back to overview]	Proportion of Participants With HBeAg Seroconversion
NCT01368497 (24) [back to overview]	Proportion of Participants With ALT ≤ 40 U/L for Males, ≤ 35 U/L for Females
NCT01368497 (24) [back to overview]	Proportion of Participants With Alanine Aminotransferase (ALT) ≤ 40 Units (U) Per Liter (L) for Males, ≤ 35 U/L for Females
NCT01368497 (24) [back to overview]	Tanner Stages of Pubic Hair Growth
NCT01368497 (24) [back to overview]	Proportion Without Detectable Antiviral Drug-resistance HBV Mutations
NCT01368497 (24) [back to overview]	Tanner Stages of Pubic Hair Growth
NCT01368497 (24) [back to overview]	Growth Measures: Z-scores Weight, Height, and Body Mass Index
NCT01368497 (24) [back to overview]	Growth Measures: Z-scores Weight, Height, and Body Mass Index
NCT01368497 (24) [back to overview]	Incidence of Adverse Events (AEs) Per Person-Year
NCT01368497 (24) [back to overview]	Incidence of Serious Adverse Events (SAEs) Per Person-Year
NCT01368497 (24) [back to overview]	Tanner Stages of Physical Growth
NCT01368497 (24) [back to overview]	Tanner Stages of Physical Growth
NCT01369199 (20) [back to overview]	Proportion of Participants With HBV DNA <20 IU/mL
NCT01369199 (20) [back to overview]	Proportion of Participants With HBsAg Seroconversion
NCT01369199 (20) [back to overview]	Proportion of Participants With HBsAg Seroconversion
NCT01369199 (20) [back to overview]	Proportion of Participants With HBeAg Loss
NCT01369199 (20) [back to overview]	Proportion of Participants With HBeAg Loss
NCT01369199 (20) [back to overview]	Proportion of Participants With ALT Normalization (Men <30 U/L, Women <20 U/L)
NCT01369199 (20) [back to overview]	Proportion of Participants With ALT Normalization (Men <30 U/L, Women <20 U/L)
NCT01369199 (20) [back to overview]	Proportion of Participants With ALT <45 U/L for Men, <30 U/L for Women
NCT01369199 (20) [back to overview]	Proportion of Participants With Alanine Aminotransferase (ALT) <45 U/L for Men, <30 U/L for Women
NCT01369199 (20) [back to overview]	Absence of Detectable Antiviral Drug-resistance HBV Mutations
NCT01369199 (20) [back to overview]	Proportion of Participants With HBsAg Loss
NCT01369199 (20) [back to overview]	Proportion of Participants With HBsAg Loss
NCT01369199 (20) [back to overview]	Proportion of Participants With HBeAg Seroconversion
NCT01369199 (20) [back to overview]	Proportion of Participants With HBeAg Seroconversion
NCT01369199 (20) [back to overview]	Proportion of Participants With HBeAg Loss (Lack of Detectable HBeAg) AND HBV DNA ≤1,000 IU/mL
NCT01369199 (20) [back to overview]	Incidence of Serious Adverse Events (SAEs) Per Person-Year
NCT01369199 (20) [back to overview]	Incidence of Adverse Events (AEs) Per Person-Year of Observation
NCT01369199 (20) [back to overview]	Proportion of Participants With HBV DNA ≤1000 IU/mL
NCT01369199 (20) [back to overview]	Proportion of Participants With HBV DNA ≤1000 IU/mL
NCT01369199 (20) [back to overview]	Proportion of Participants With HBV DNA <20 IU/mL
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants With HBeAg Seroconversion
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants Who Achieved ALT Normalization
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay
NCT01438424 (26) [back to overview]	Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing
NCT01438424 (26) [back to overview]	Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240
NCT01438424 (26) [back to overview]	Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing
NCT01438424 (26) [back to overview]	Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs
NCT01438424 (26) [back to overview]	Overall Study: Mean HBV DNA Level by PCR Assay
NCT01438424 (26) [back to overview]	Overall Study: Mean Alanine Transaminase (ALT) Levels
NCT01438424 (26) [back to overview]	Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay
NCT01438424 (26) [back to overview]	Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)
NCT01438424 (26) [back to overview]	Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay
NCT01438424 (26) [back to overview]	Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
NCT01438424 (26) [back to overview]	Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
NCT01438424 (26) [back to overview]	Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
NCT01438424 (26) [back to overview]	Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)
NCT01438424 (26) [back to overview]	Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)
NCT01438424 (26) [back to overview]	Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
NCT01438424 (26) [back to overview]	Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)
NCT01438424 (26) [back to overview]	Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)
NCT01438424 (26) [back to overview]	Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
NCT01438424 (26) [back to overview]	Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)
NCT01438424 (26) [back to overview]	Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
NCT02065336 (16) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02065336 (16) [back to overview]	Number of Participants With Negative Bee Venom Allergy Test Results at Baseline, Day 29, and Day 85
NCT02065336 (16) [back to overview]	Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)
NCT02065336 (16) [back to overview]	Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)
NCT02065336 (16) [back to overview]	Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)
NCT02065336 (16) [back to overview]	Change From Baseline Over Time in Quantitative Hepatitis B Surface Antigen (HBsAG)
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Half-Life (t1/2), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Cohorts 1-5 Only
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Apparent Volume of Distribution During the Terminal Phase (Vz), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC0-24), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Clearance (CL), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Maximum Observed Plasma Concentration (Cmax), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Terminal Elimination Rate Constant (Kel), Cohorts 1-5
NCT02065336 (16) [back to overview]	Pharmacokinetics of ARC-520 Product Constituents AD0009 and AD0010: Volume in Steady State (Vss), Cohorts 1-5
NCT02065336 (16) [back to overview]	Change From Baseline in Entecavir Plasma Trough Concentration, Cohorts 1-7
NCT02263079 (19) [back to overview]	Serum Concentration of Peg-INF-Alfa-2A
NCT02263079 (19) [back to overview]	Percentage of Participants With AEs Leading to Dose Modification or Interruption
NCT02263079 (19) [back to overview]	Percentage of Participants With Loss of HBsAg
NCT02263079 (19) [back to overview]	Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation
NCT02263079 (19) [back to overview]	Change From Baseline in HBV DNA Levels in the Peg-INF-Alfa-2A (Treated) Arm
NCT02263079 (19) [back to overview]	Change From Baseline in HBV DNA Levels in the Untreated Control Participants
NCT02263079 (19) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02263079 (19) [back to overview]	Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL
NCT02263079 (19) [back to overview]	Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL
NCT02263079 (19) [back to overview]	Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL
NCT02263079 (19) [back to overview]	Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL
NCT02263079 (19) [back to overview]	Percentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)
NCT02263079 (19) [back to overview]	Percentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)
NCT02263079 (19) [back to overview]	Percentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)
NCT02263079 (19) [back to overview]	Percentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)
NCT02263079 (19) [back to overview]	Percentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe
NCT02263079 (19) [back to overview]	Percentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe
NCT02263079 (19) [back to overview]	Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs
NCT02263079 (19) [back to overview]	Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs
NCT02452528 (1) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Deaths, and Discontinuations Due to Adverse Events (AEs)
NCT02577029 (1) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs Considered Possibly or Probably Related to Treatment
NCT02604199 (3) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs
NCT02604199 (3) [back to overview]	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) Over Time
NCT02604199 (3) [back to overview]	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113
NCT02604212 (26) [back to overview]	Change From Baseline at Day 99 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 99 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 99 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 85 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 85 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 85 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 71 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 71 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 71 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 57 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 57 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 43 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 43 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 43 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 29 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 29 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 15 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 15 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 15 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 113 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 113 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline at Day 113 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline in Quantitative Hepatitis B Surface Antigen (Log qHBsAg) at Day 113
NCT02604212 (26) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Due to AEs
NCT02604212 (26) [back to overview]	Change From Baseline at Day 57 in Log qHBsAg, by Category
NCT02604212 (26) [back to overview]	Change From Baseline in Log qHBsAg Over Time
NCT02726789 (4) [back to overview]	Number of Patients Experiencing Reductions in Serum HBsAg
NCT02726789 (4) [back to overview]	Number of Patients Experiencing Reductions in Serum HBV DNA
NCT02726789 (4) [back to overview]	Number of Patients Experiencing Serum Anti-HBs > 10 mIU / ml
NCT02726789 (4) [back to overview]	Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events.
NCT02738008 (1) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02797522 (2) [back to overview]	Number of Participants With TEAEs: CHB Participants
NCT02797522 (2) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs): Healthy Volunteers
NCT02881008 (7) [back to overview]	Proportion of Patients With HBsAg Response at 24 Week of Therapy
NCT02881008 (7) [back to overview]	Proportion of Patients With HBV DNA Response at Week 24 of Therapy
NCT02881008 (7) [back to overview]	Proportion of Patients With HBV DNA Response at Week 12 of Therapy
NCT02881008 (7) [back to overview]	Proportion of Patients With Biochemical Response at 24 Weeks of Therapy
NCT02881008 (7) [back to overview]	Proportion of Patients With cccDNA Response at 24 Week of Therapy
NCT02881008 (7) [back to overview]	Proportion of Patients With HBsAg Response at 12 Week of Therapy
NCT02881008 (7) [back to overview]	Proportion of Patients With Biochemical Response at 12 Weeks of Therapy
NCT03083821 (6) [back to overview]	Apparent Total Body Clearance (CLT/F)
NCT03083821 (6) [back to overview]	Area Under the Concentration-time Curve in One Dosing Interval [AUC(TAU)]
NCT03083821 (6) [back to overview]	Maximum Observed Plasma Concentration (Cmax)
NCT03083821 (6) [back to overview]	Observed Plasma Concentration at 24 Hours Postdose (C24)
NCT03083821 (6) [back to overview]	Time of Maximum Observed Plasma Concentration (Tmax)
NCT03083821 (6) [back to overview]	Trough Observed Plasma (Predose) Concentration (Ctrough)
NCT03576066 (12) [back to overview]	Trough Levels of Tenofovir Alafenamide (TAF) on ABI-H0731 + SOC NUC Therapy as Compared With Placebo + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Trough Levels of Tenofovir Disoproxil Fumarate (TDF) on ABI-H0731 + SOC NUC Therapy as Compared With Placebo + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Number of Participants With a Clinically-significant Change in Vital Signs
NCT03576066 (12) [back to overview]	Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + NUC Therapy as Compared With Placebo + NUC Therapy
NCT03576066 (12) [back to overview]	Number of Participants With One or More Abnormal Safety Laboratory Result
NCT03576066 (12) [back to overview]	Number of Participants With One or More Adverse Events
NCT03576066 (12) [back to overview]	Number of Participants With Premature Study Discontinuation
NCT03576066 (12) [back to overview]	Change in Mean log10 Serum HBeAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUC
NCT03576066 (12) [back to overview]	Change in Mean log10 Serum HBsAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUC
NCT03576066 (12) [back to overview]	Trough Levels of ABI-H0731 on ABI-H0731 + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Trough Levels of Entecavir (ETV) on ABI-H0731 + SOC NUC Therapy as Compared With Placebo + SOC NUC Therapy
NCT03576066 (12) [back to overview]	Number of Participants With a Clinically-significant Electrocardiogram Abnormality
NCT03577171 (10) [back to overview]	Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV
NCT03577171 (10) [back to overview]	Number of Participants With a Decline in Viral DNA to Below Limit of Quantitation on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV
NCT03577171 (10) [back to overview]	Number of Participants With One or More Abnormal Safety Laboratory Result
NCT03577171 (10) [back to overview]	Trough Levels of ABI-H0731 on ABI-H0731 + SOC ETV Therapy
NCT03577171 (10) [back to overview]	Number of Participants One or More Adverse Events
NCT03577171 (10) [back to overview]	Number of Participants With a Clinically-significant Change in Vital Signs
NCT03577171 (10) [back to overview]	Number of Participants With a Clinically-significant Electrocardiogram Abnormality
NCT03577171 (10) [back to overview]	Number of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at Week 24 on ABI-H0731 + SOC ETV as Compared to Placebo + SOC ETV
NCT03577171 (10) [back to overview]	Number of Participants With Premature Study Discontinuation
NCT03577171 (10) [back to overview]	Trough Levels of ETV on ABI-H0731 + ETV Therapy as Compared With Placebo + ETV Therapy
NCT03780543 (5) [back to overview]	Number of Subjects With Adverse Events
NCT03780543 (5) [back to overview]	Number of Subjects With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Have Normal ALT at End of Treatment (EOT) and End of Study (EOS)
NCT03780543 (5) [back to overview]	Sustained Viral Response (SVR) at 24 Weeks Off Treatment
NCT03780543 (5) [back to overview]	Number of Subjects With Suppression/Loss of Viral HBeAg Antigen/DNA on Combination Treatment Whose Viral Antigens Rebound Off Therapy
NCT03780543 (5) [back to overview]	Number of Subjects With Suppression/Loss of Viral Core-related Antigen/DNA on Combination Treatment Whose Viral Antigens Rebound Off Therapy
NCT04398134 (4) [back to overview]	Percentage of Participants With Premature Treatment Discontinuation
NCT04398134 (4) [back to overview]	Percentage of Participants With Adverse Events
NCT04398134 (4) [back to overview]	Change From Baseline in Mean log10 HBV DNA
NCT04398134 (4) [back to overview]	Percentage of Participants With Abnormal Laboratory Results
NCT04465916 (2) [back to overview]	HBsAg Change (Δ log10) From Day 1 to Week 16 of Treatment
NCT04465916 (2) [back to overview]	Virologic Failure Rate
NCT04781647 (10) [back to overview]	Number of Participants With an Adverse Event
NCT04781647 (10) [back to overview]	Number of Participants With a Laboratory Abnormality
NCT04781647 (10) [back to overview]	Number of Participants With Premature Discontinuation of Treatment
NCT04781647 (10) [back to overview]	Mean Change From Baseline in HBsAg
NCT04781647 (10) [back to overview]	Plasma Concentration of ABI-H0731
NCT04781647 (10) [back to overview]	Mean Change From Baseline in HBV pgRNA
NCT04781647 (10) [back to overview]	Plasma Concentration of ABI-H0731
NCT04781647 (10) [back to overview]	Mean Change From Baseline in HBeAg
NCT04781647 (10) [back to overview]	Mean Change From Baseline in HBcrAg
NCT04781647 (10) [back to overview]	Mean Change From Baseline HBV DNA
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) On-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With One or More Abnormal Laboratory Result
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) Off-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686 (20) [back to overview]	Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Hepatitis B Core-related Antigen (HBcrAg) Off-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With One or More Adverse Events (AEs)
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Number of Participants With Premature Treatment Discontinuation Due to AEs
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA Off-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 HBV RNA On-Treatment
NCT04820686 (20) [back to overview]	Change From Baseline in Mean log10 Serum Hepatitis B Surface Antigen (HBsAg) Off-Treatment

Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48

(NCT00065507)
Timeframe: Baseline, Week 4, Week 8, Week 12, Week 24, Week 48

Intervention	Participants (Number)
	Baseline	Week 4	Week 8	Week 12	Week 24	Week 48
Adefovir (ADV) 10 mg	1	6	11	16	24	34
Entecavir (ETV) 1.0 mg	3	23	34	37	49	57

Intervention	participants (Number)
	Any Adverse Events	Hepatic Neoplasm, Malignant	Basal Cell Carcinoma	Lymph Node Cancer, Metastatic	Hepatic Mass
Adefovir (ADV) 10 mg	18	18	0	0	0
Entecavir (ETV) 1.0 mg	14	12	1	1	1

Intervention	participants (Number)
	Hemoglobin	International Normalized Ratio	Platelet Count	Prothrombin Time	Bicarbonate, Low	Chloride, Serum, Low	Bicarbonate/Carbon Dioxide, Low	Potassium, Serum, High	Sodium, Serum	Sodium, Serum, Low	Lipase, Total (colorimetric assay)	Alanine Aminotransferase (ALT)	Albumin	Alkaline Phosphatase (ALP)	Aspartate Aminotransferase (AST)	Bilirubin, Total	G-Glutamyl Transferase (GGT)	Glucose, Fasting Serum, High	Creatinine	Phosphorus, inorganic	Blood, urine	Glucose, urine	Protein, urine	Neutrophils (relative)	Neutrophils + Bands (relative)	Neutrophils (absolute)
Cumulative - Adefovir (ADV) 10 mg	10	32	24	11	4	2	4	0	5	5	25	4	3	1	7	25	10	0	0	6	22	13	4	1	8	7
Cumulative - Entecavir (ETV) 1.0 mg	11	40	25	25	4	2	4	1	6	6	23	5	9	1	9	24	9	1	2	0	18	17	2	0	4	5
Week 48 - Adefovir (ADV) 10 mg	8	22	21	7	4	2	4	0	3	3	18	1	3	1	3	18	6	0	0	4	13	11	2	1	4	3
Week 48 - Entecavir (ETV) 1.0 mg	8	30	20	20	3	2	3	1	6	6	17	3	9	0	7	19	1	0	1	0	13	11	1	0	2	2

Intervention	mg/dL (Mean)
	Baseline Value (n=100; n=91)	Change at Week 4 (n=98; n=88)	Change at Week 8 (n=92; n=82)	Change at Week 12 (n=88;l n=80)	Change at Week 24 (n=81; n=77)	Change at Week 36 (n=76; n=70)	Change at Week 48 (n=72; n=63)
Adefovir (ADV) 10 mg	2.50	0.21	-0.17	-0.28	-0.14	-0.09	-0.10
Entecavir (ETV) 1.0 mg	2.80	-0.06	0.11	-0.20	-0.41	-0.36	-0.61

Intervention	seconds (Mean)
	Baseline Value (n=100; n=91)	Change at Week 4 (n=98; n=87)	Change at Week 8 (n=91; n=79)	Change at Week 12 (n=88; n=80)	Change at Week 24 (n=80; n=77)	Change at Week 48 (n=72; n=63)
Adefovir (ADV) 10 mg	15.35	0.03	0.06	-0.05	-0.18	-0.52
Entecavir (ETV) 1.0 mg	16.28	-0.08	-0.10	-0.29	-0.75	-0.99

Intervention	units on a scale (Mean)
	Baseline Value (n=100; n=91)	Week 4 (n=97; n=87)	Week 8 (n=90; n=79)	Week 12 (n=88; n=80)	Week 24 (n=80; n=77)	Week 36 (n=75; n=70)	Week 48 (n=72; n=62)
Adefovir (ADV) 10 mg	15.3	0.1	-0.4	-0.9	-0.9	-1.2	-1.7
Entecavir (ETV) 1.0 mg	17.1	-0.1	-0.8	-1.2	-2.0	-2.3	-2.6

Intervention	participants (Number)
	Any AE	Grade 3/4 AEs	SAEs	Deaths	HCC	Discontinuations due to AEs	Confirmed creatinine increase >= 0.5 mg/dL
Adefovir (ADV) 10 mg	86	42	59	29	18	5	21
Entecavir (ETV) 1.0 mg	91	55	70	23	12	7	17

Intervention	10*9 c/L (Mean)
	Baseline Value (n=97; n=91)	Change at Week 4 (n=90; n=85)	Change at Week 8 (n=82; n=76)	Change at Week 12 (n=85; n=79)	Change at Week 24 (n=77; n=76)	Change at Week 36 (n=72; n=69)	Change at Week 48 (n=68; n=63)
Adefovir (ADV) 10 mg	93.31	-2.14	3.88	-0.81	-2.89	1.32	3.05
Entecavir (ETV) 1.0 mg	87.32	-0.93	3.55	4.36	2.47	6.56	10.19

Intervention	units on a scale (Mean)
	Baseline Value (n=100, n=91)	Change at Week 4 (n=90; n=85)	Change at Week 8 (n=90; n=79)	Change at Week 12 (n=87; n=80)	Change at Week 24 (n=80; n=77)	Change at Week 36 (n=75; n=70)	Change at Week 48 (n=72; n=64)
Adefovir (ADV) 10 mg	8.4	-0.3	-0.3	-0.3	-0.7	-0.9	-1.3
Entecavir (ETV) 1.0 mg	8.8	-0.4	-0.4	-0.6	-1.2	-1.6	-1.7

Intervention	HCC events (Number)
	Weeks 0-4 (n=102; n=89)	Weeks 4-8 (n=99; n=86)	Weeks 8-12 (n=96; n=83)	Weeks 12-16 (n=90; n=80)	Weeks 16-20 (n=87; n=77)	Weeks 20-24 (n=86; n=75)	Weeks 24-28 (n=81; n=71)	Weeks 28-32 (n=78; n=70)	Weeks 32-36 (n=77; n=66)	Weeks 36-40 (n=77; n=64)	Weeks 40-44 (n=73; n=62)	Weeks 44-48 (n=71; n=62)
Adefovir (ADV) 10 mg	3	5	6	9	11	14	15	17	18	20	20	22
Entecavir (ETV) 1.0 mg	2	5	10	11	11	16	17	17	17	19	21	24

Intervention	participants (Number)
	Liver Transplant: Yes	Liver Transplant: No
Adefovir (ADV) 10 mg	3	86
Entecavir (ETV) 1.0 mg	11	91

Intervention	participants (Number)
	ALT flares	ALT flares, no clinical events/lab abnormalities	ALT flares, with clinical events/lab abnormalities
Adefovir (ADV) 10 mg	1	0	1
Entecavir (ETV) 1.0 mg	2	1	1

Intervention	log10 copies/mL (Number)
	First slope (first phase of viral decay)	Second slope (second phase of viral decay)
Adefovir	-0.329	-0.024
Entecavir	-0.391	-0.034

Intervention	percent effective (Number)
	Efficacy in blocking virus production - ε	Effectiveness in blocking de novo infections - η
Adefovir	99.46	5.87
Entecavir	99.87	6.07

Intervention	per day (Number)
	Viral Clearance - c	Infected cell death - δ
Adefovir	0.91	0.04
Entecavir	1.70	0.08

Intervention	Participants (Number)
	ALT increased	Lipase increased	Blood phosphorus decreased	Liver function test abnormal	Platelet count decreased	Protein urine present
Adefovir	2	2	1	1	1	1
Entecavir	1	1	0	0	0	0

Intervention	Participants (Number)
	Death	Serious AE	Discontinuation due to AE	Malignant neoplasm	On Treatment: Any AE	On Treatment: Headache	On Treatment: Upper Respiratory Infection	On Treatment: Influenza	On Treatment: Nasopharyngitis	On Treatment: Pyrexia	On Treatment: Back Pain	On Treatment: Grade 3-4 AEs	ALT Flare	Hepatic SAE
Adefovir	0	3	1	0	27	6	8	4	6	6	5	5	1	2
Entecavir	0	1	0	0	28	9	8	6	4	4	0	2	0	1

Intervention	percentage of participants (Number)
	HBeAg Loss	HBeAg Seroconversion
Entecavir	0.0	0.0
FTC/TDF	33.3	13.3
Overall	20.0	11.4
Tenofovir DF	14.3	14.3

Intervention	percentage of participants (Number)
	HBsAg Loss	HBsAg Seroconversion
Entecavir	0.0	0.0
FTC/TDF	0.0	0.0
Overall	0.0	0.0
Tenofovir DF	0.0	0.0

Intervention	percentage of participants (Number)
	<50 IU/mL (< 300 copies/mL)	50 to <172 IU/mL (300 to < 103 copies/mL)	172 to <1720 IU/mL (103 to < 104 copies/mL)	1720 to <17200 IU/mL (104 to < 105 copies/mL)	≥17,200 IU/mL (≥105 copies/mL)	Missing
Black / African American	72.5	0	10.0	5.0	0	12.5
Total	69.6	0	10.9	4.3	0	15.2

Intervention	log10 IU/mL (Mean)
	Baseline	HBV DNA at Week 48	Change from baseline
Black / African American	7.1	1.88	-5.22
Total	7.0	1.87	-5.18

entecavir

Description

Cross-References

Synonyms (130)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (6)

Protein Targets (25)

Potency Measurements

Inhibition Measurements

Activation Measurements

Biological Processes (139)

Molecular Functions (70)

Ceullar Components (53)

Bioassays (354)

Research

Studies (1,787)

Market Indicators

Research Demand Index: 87.63

Study Types

Clinical Trials (237)

Trial Overview

Trial Outcomes

Number of Subjects Achieving Composite Endpoint (HBV DNA < 10*4 Copies/mL by PCR Assay and Normal ALT [≤ 1.0 x ULN]) Through Week 48

Number of Participants With Improvement or No Worsening in Child-Pugh Score From Baseline to Week 48

Number of Participants With Malignant Neoplasms - On Treatment or During 24-Week Follow-up Period

Number of Participants With Treatment-Emergent Grade 3/4 Laboratory Abnormalities - Week 48 and Cumulative Data

Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 48

Number of Participants With HBV DNA < 300 Copies/mL by PCR At Week 24

Mean Change From Baseline in Total Bilirubin Through Week 48

Mean Change From Baseline in Prothrombin Time Through Week 48

Mean Change From Baseline in Model for End-Stage Liver Disease (MELD) Scores From Baseline Through Week 48

Improvement or No Worsening in MELD Score Through Week 48

Cumulative Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, HCC, Discontinuations Due to AEs, and Confirmed Creatinine Increase >=0.5 mg/dL

Change From Baseline in Platelet Count Through Week 48

Change From Baseline in Child-Pugh Score Through Week 48

Change From Baseline in Albumin Through Week 48

>=2-Point Reduction From Baseline in Child-Pugh Score Through Week 48

Change From Baseline in HBV DNA by PCR at Week 48

Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24

Participants Achieving Albumin Normalization Through Week 48

Participants Achieving Platelet Count Normalization Through Week 48

Participants Achieving Prothrombin Time Normalization Through Week 48

Participants Achieving Total Bilirubin Normalization Through Week 48

Number of Hepatocellular Carcinoma (HCC) Events at Different Time Points Through Week 48

Number of Participants Achieving Alanine Transaminase (ALT) Normalization (≤1.0 x Upper Limit of Normal [ULN]) at Weeks 24 and 48

Number of Participants Undergoing Liver Transplant - On-Treatment or 24-Week Follow-Up

Number of Participants With Alanine Aminotransferase (ALT) Flares - On Treatment

Number of Participants With Improvement in Child-Pugh Class at Week 24 and Week 48

HBV DNA Viral Kinetics - Spline Model

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Efficacy in Blocking Virus Production and de Novo Infections

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Viral Clearance Rate and Infected Cell Death Rate

Summary of Safety - Laboratory Abnormalities Reported as Clinical AEs

Summary of Safety - Most Frequent (> 10%) Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Deaths

Alanine Aminotransferase (ALT) Normalization

Change From Baseline in HBV DNA by PCR Assay at Week 48

Change From Baseline in Hepatitis B Virus DNA (HBV DNA) by Polymerase Chain Reaction (PCR) Assay at Week 12

HBV DNA Viral Kinetics Estimates of Exponential Decay Model - Half-Life of Free Virus

Viral Load Undetectable (HBV DNA <300 Copies/mL)

Percentage of Participants With HBeAg Loss and HBeAg Seroconversion at Week 96 (for Participants Who Were HBeAg Positive at Baseline)

Median Change in MELD Score From Baseline at Week 96

Median Change in MELD Score From Baseline at Week 168

Median Change in MELD Score From Baseline at Week 144

In the Subset of Participants Undergoing Liver Transplantation, Time to Recurrence of Hepatitis B, Defined as 2 Consecutive Plasma HBV DNA Concentrations ≥ 400 Copies/mL or 2 Consecutive HBsAg(+) Results

Median DAVG in Plasma HBV DNA Levels at 144 Weeks Relative to Baseline

Median DAVG in Plasma HBV DNA Levels at 168 Weeks Relative to Baseline

Median DAVG in Plasma HBV DNA Levels at 96 Weeks Relative to Baseline

Median Time-averaged Change (DAVG) in Plasma Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels at 48 Weeks Relative to Baseline

Percent Probability of a Confirmed Increase in Serum Creatinine of ≥ 0.5 mg/dL From Baseline or a Confirmed Serum Phosphorus Level < 2.0 mg/dL

Percent Probability of Tolerability Failure

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 144

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 168

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 48

Percentage of Participants With a Decrease in CPT Score of ≥ 2 Points From Baseline at Week 96

Percentage of Participants With an Increase in Child-Pugh Turcotte (CPT) Score of ≥ 2 Points at Weeks 48

Intervention	participants (Number)
	Alanine aminotransferase-OT	Alanine aminotransferase-OF; n=26 , 29	Aspartate aminotransferase-OT	Aspartate aminotransferase-OF; n=26 , 29	Alkaline Phosphatase-OT	Alkaline Phosphatase-OF; n=26 , 29	Albumin-OT	Albumin-OF; n=26 , 29	Total Bilirubin-OT	Total Bilirubin-OF; n=26 , 29	Serum Lipase-OT	Serum Lipase-OF; n=26 , 29	Creatinine-OT	Creatinine-OF; n=26 , 29	Blood Urea Nitrogen-OT	Blood Urea Nitrogen-OF; n=26 , 29	Hyperglycemia-OT	Hyperglycemia-OF; n=26 , 29	Hypoglycemia-OT	Hypoglycemia-OF; n=26 , 29	Hypernatremia-OT	Hypernatremia-OF; n=26 , 29	Hyponatremia-OT	Hyponatremia-OF; n=26 , 29	Hyperkalemia-OT	Hyperkalemia-OF; n=26 , 29	Hypokalemia-OT	Hypokalemia-OF; n=26 , 29	Hyperchloremia-OT	Hyperchloremia-OF; n=26 , 29	Hypochloremia-OT	Hypochloremia-OF; n=26 , 29
Black / African American	37	3	33	2	3	1	3	0	7	3	12	1	3	0	2	0	14	5	5	1	0	0	3	0	0	0	3	0	0	0	0	0
Total	43	4	38	3	3	1	5	0	7	4	14	1	3	0	2	0	15	5	5	1	0	0	3	1	0	0	3	0	0	0	0	0

Intervention	participants (Number)
	Hemoglobin-OT	Hemoglobin-OF; n=26 , 29	White Blood Cells-OT	White Blood Cells-OF; n=26 , 29	Neutrophils -OT	Neutrophils-OF; n=26 , 26	Platelets-OT	Platelets-OF; n=26 , 29	International Normalized Ratio-OT	International Normalized Ratio-OF; n=26 , 29
Black / African American	1	0	15	7	13	4	4	0	18	4
Total	2	0	18	8	13	4	4	0	23	4

Intervention	Participants (Number)
	Platelets	Prothrombin time	Neutrophils	AST	ALT	Total bilirubiin	Creatinine	Lipase	Potassium	Glucose, fasting
Entecavir, 0.5 mg + Placebo	1	1	0	0	0	1	2	2	0	3
Lamivudine, 100 mg + Placebo	1	0	1	3	6	3	0	4	1	2

Intervention	Participants (Number)
	Week 24: HBV DNA <10^3	Week 24: HBV DNA <10^4	Week 24: HBV DNA <10^5	Week 48: HBV DNA <10^3	Week 48: HBV DNA <10^4	Week 48: HBV DNA <10^5	Week 96: HBV DNA <10^3	Week 96: HBV DNA <10^4	Week 96: HBV DNA <10^5
Entecavir, 0.5 mg + Placebo	54	54	54	54	55	55	53	53	53
Lamivudine, 100 mg + Placebo	46	53	59	45	50	52	38	42	45

Intervention	Participants (Number)
	At 24 Weeks	At 48 Weeks	At 96 Weeks
Entecavir, 0.5 mg + Placebo	43	48	49
Lamivudine, 100 mg + Placebo	37	38	33

Intervention	Participants (Number)
	Viral rebound	Drug-resistant mutations
Entecavir, 0.5 mg + Placebo	1	0
Lamivudine, 100 mg + Placebo	26	13

Intervention	Percetage of participants (Number)
	At 48 Weeks	At 96 Weeks	At 144 Weeks	At 192 Weeks	At 240 Weeks
Entecavir, 0.5 mg + Placebo	94.64	94.64	67.86	69.64	67.86
Lamivudine, 100 mg + Placebo	60.94	48.44	34.38	25.00	15.63

Intervention	Participants (Number)
	SAEs	Discontinuations due to AEs	Any nonserious AEs	Nonserious AEs related to study conditions	SAEs related to study conditions
Entecavir, 0.5 mg + Placebo	7	0	48	1	0
Lamivudine, 100 mg + Placebo	17	1	49	6	0

Intervention	U/L (Mean)
Entecavir, 0.5 mg + Placebo	31.5
Lamivudine, 100 mg + Placebo	43.26

Intervention	Percentage of participants (Number)
Entecavir, 0.5 mg + Placebo	92.86
Lamivudine, 100 mg + Placebo	67.19